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Abstract 
Preeclampsia is a pregnancy-specific condition characterized by new-onset hypertension and 
proteinuria associated with placental ischemia. Because no cure exists besides parturition, 
preeclampsia remains a leading cause of maternal and perinatal death and morbidity.  New 
management strategies are urgently needed to attenuate maternal symptoms and prolong 
gestation.  Immune activity is normally heightened in pregnancy and has been shown to increase 
even further in preeclampsia, as evidenced by elevations in innate immune complement activation 
products, including C3a.  Decreased circulating free vascular endothelial growth factor (VEGF) is 
a known contributor to preeclampsia and previous studies have demonstrated a link between 
VEGF and complement. We therefore hypothesized that complement activation is critical to 
placental ischemia-induced hypertension.  To test this, we used the Reduced Utero-placental 
Perfusion Pressure (RUPP) model of placental ischemia in the rat to induce hypertension and 
explore the effects of inhibiting complement activation and antagonizing a specific complement 
receptor in this model.  The data demonstrate that complement activation occurred following 
placental ischemia and administration of soluble complement receptor 1, an inhibitor of 
complement activation, successfully prevented complement activation and abrogated the 
hypertension without influencing circulating free VEGF concentrations.  To determine the 
specific complement component responsible, we used a C3a receptor antagonist to inhibit C3a-
mediated cellular responses that may be important in placental ischemia-induced hypertension.  
The C3a receptor antagonist attenuated the hypertension and improved placental efficiency and 
did not affect circulating free VEGF, suggesting complement may be important in hypertension 
apart from circulating free VEGF concentrations.  Overall, these data suggest a potentially 
valuable role for specific complement inhibition in managing the symptoms of preeclampsia. 
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Introduction 
The following investigates the complex physiological relationships involved in 
preeclampsia, a multi-systemic condition specific to pregnancy. Using the integrative 
principle of feedback loops, we manipulated several key factors implicated as important 
to the pathophysiology of preeclampsia. We incorporated a broad scope of complexities, 
ranging from molecular to whole-organism, to study preeclampsia from a unique 
integrative perspective. 
 
Chapter 1 
Background  
Pathophysiology of preeclampsia 
Preeclampsia is a complex condition specific to human pregnancy that is manifest 
by new-onset maternal hypertension and proteinuria, often accompanied by intrauterine 
growth restriction (Steegers et al., 2010).  Preeclampsia is a widespread disorder affecting 
approximately 2-8% of pregnancies (Gilbert et al., 2007; Maynard et al., 2008) and it 
involves multiple systems, making it a leading cause of maternal and perinatal morbidity 
and mortality.  Currently, no definitive cures exist besides delivery of the conceptus, and 
lack of treatment may lead to progression to eclampsia with seizures and death. Extensive 
studies have identified various pathophysiological characteristics of the condition, yet the 
etiology of preeclampsia remains unclear (Sibai et al., 2005; Steegers et al., 2010).  
Understanding the underlying mechanisms of preeclampsia may facilitate the 
development of effective management options to improve both maternal and fetal health. 
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Clinically, preeclampsia is defined as hypertension (140/90 mmHg) and 
proteinuria (300 mg protein in the urine measured over 24 hours) and is typically 
associated with widespread endothelial damage and dysfunction. Symptoms may become 
evident as early as 20 weeks (“early-onset” if before 34 weeks, “late-onset” after 34 
weeks). Early-onset preeclampsia has a different profile than late-onset and is associated 
with more pronounced angiogenic imbalance, more severe intrauterine growth restriction, 
and higher morbidity (Cunningham et al., 2009) than late-onset. Variants of preeclampsia 
exist, such as Hemolysis, Elevated Liver enzymes, and Low Platelets (HELLP) 
syndrome, and the development of seizures with hypertension and proteinuria indicates 
progression to eclampsia. 
Healthy pregnancies require numerous physiological changes to occur to 
accommodate proper placental, embryonic and ultimately fetal development. In early 
human development, embryonic cells differentiate into an outer layer of trophoblastic 
cells and an inner mass of cells called the embryoblast around eight days post-
fertilization. The trophoblastic cells normally burrow into the endometrial layer of the 
uterine wall to anchor the embryo and eventually establish the placenta.  These cells are 
responsible for downregulating epithelial adhesion molecule expression and instead 
assume adhesion molecules characteristic of endothelial cells, a process termed 
pseudovasculogenesis.  During this time, coiled maternal blood vessels called spiral 
arteries partially uncoil and dilate to reduce resistance and increase blood flow to the 
placenta.  Inadequate trophoblastic invasion results in abnormalities in maternal arterial 
remodeling and ultimately leads to abnormal placentation, reduced uterine perfusion, and 
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placental ischemia (Caluwaerts et al., 2004; Bainbridge et al., 2009), which are 
implicated as critical precursors to preeclampsia (Gilbert et al., 2008).   
Because the spiral arteries do not properly dilate in women destined to be 
preeclamptic, uterine circulation passes through higher resistance vessels and does not 
supply adequate blood to the feto-placental unit. The ischemic (and therefore, hypoxic) 
placenta stimulates the production and release of a suite of factors that are associated with 
endothelial dysfunction, hypertension, and oxidative stress.  Alterations in these factors, 
including soluble fms-like tyrosine kinase 1 (sFlt-1) (a soluble form of the receptor to 
vascular endothelial growth factor (VEGF)), VEGF, endoglin, and placental growth 
factor (PlGF) have been demonstrated to contribute to the development of preeclampsia 
in both low- and high-risk women (Powers et al., 2010). 
Other factors are thought to contribute to the pathophysiology of preeclampsia 
and are discussed below.  These are summarized in Table 1 and include nitric oxide, 
angiotensin, VEGF, sFlt-1, and immune factors. 
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Table 1. Factors involved in the pathophysiology of preeclampsia. 
Factor Function 
Levels in preeclamptic 
pregnancy vs normal 
pregnancy 
Nitric oxide (NO) 
Vasodilator; necessary 
component for angiogenesis 
Decreased 
Angiotensin 
Regulates blood pressure 
through renin-angiotensin-
aldosterone system 
Increased 
Vascular endothelial growth 
factor (VEGF), placental 
growth factor (PlGF) 
Vasodilators through NO 
stimulation; pro-angiogenic 
Decreased 
Soluble fms-like tyrosine 
kinase-1 (sFlt-1) 
Vasoconstrictor; soluble 
receptor for VEGF 
Increased 
Interleukin-6 
CD4+ T cells 
Markers of inflammation Increased 
Complement activation 
products (C3a, C5a, Bb) 
Indicate innate immune 
response 
Increased 
 
 
Nitric oxide. Oxidative stress, or the presence of reactive oxygen species 
overwhelming the buffering effects of antioxidants, has long been considered a primary 
cause in the development of endothelial dysfunction leading to the manifestation of 
symptoms in preeclampsia (Roberts & Cooper, 2001).  An increase in oxidative stress has 
been demonstrated following placental ischemia and may have a role in renal dysfunction 
and hypertension (Sedeek et al., 2008).  Several factors indicative of oxidative stress have 
recently been identified in women with early-onset preeclampsia, such as 8-isoprostane 
(Wikström et al., 2009), malondialdehyde (Rani et al., 2010), and myeloperoxidase 
(Kurdoglu et al., 2012), and onset of placental ischemia precedes an apparent decrease in 
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innate antioxidant activity (Sedeek et al., 2008).  In preeclampsia, endothelial nitric oxide 
synthase (eNOS) has decreased activity and uncouples to produce superoxide rather than 
nitric oxide (NO).  NO is a necessary component for angiogenesis (Ahmed, 2011) and its 
production is increased by vascular endothelial growth factor (VEGF) receptor 
stimulation. Studies have shown that inhibition of VEGF receptors leads to a decrease in 
NO and, consequently, a lack of vasodilation (Robinson et al., 2010). Decreases in NO 
are also associated with hypertension in preeclampsia (Li et al., 2012). 
NO and prostaglandins also mediate increases in glomerular filtration rate (GFR) 
and renal plasma flow (RPF) associated with decreased vascular resistance and increased 
blood volume. In normal pregnancy, maternal blood volume increases approximately 40-
50% compared to non-pregnant volume (Conrad et al., 2009). The increase in GFR and 
RPF are seemingly independent of the larger blood volume (Conrad et al., 2009), and 
clinical analysis has shown this normal increase in blood volume to be minimized or even 
absent in women with eclampsia (Sibai & Mabie, 1991).  Preeclampsia is associated with 
a decrease in glomerular filtration rate (GFR) and renal perfusion, which, in concert with 
the often observed hyperuricemia, result in overall decreased renal clearance and 
proteinuria. Proteinuria is diagnosed by the presence of 300 mg of protein in the urine 
over a 24-hour period and is indicative of renal endothelial damage. 
Angiotensin. Hypertension is defined as a systolic blood pressure greater than or 
equal to 140 mmHg or a diastolic blood pressure greater than or equal to 90 mmHg.  The 
renin-angiotensin-aldosterone system is commonly considered the root of many 
hypertensive conditions, and women with preeclampsia have higher placental expression 
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of angiotensinogen and angiotensin I receptor mRNAs, and higher levels of angiotensin 
II in the placenta (Anton et al., 2008). In addition, it has been long recognized that 
preeclamptic women are hypersensitive to angiotensin II (Gilbert et al., 2008). 
Angiotensin II is known to stimulate induction of matrix metalloproteinase-9, an enzyme 
that breaks down extracellular matrix to aid in tissue remodeling, and transforming 
growth factor (TGF)-β, a pro-angiogenic peptide (Dumont et al., 2007; Venkatesha et al., 
2006). Placental increases in TGF-β concentrations have been observed in preeclamptic 
women and may be implicated as a contributor to the pathogenesis of preeclampsia 
because of its deterring impact on the syncitialization process (Raymond et al., 2011). 
VEGF. Endothelial dysfunction leading to hypertension and proteinuria may stem 
from an imbalance in circulating angiogenic factors.  VEGF is a pro-angiogenic factor 
and has a demonstrated role in decreasing blood pressure and vascular tonicity through 
stimulating NO and vasodilatory prostacyclin activity.  Placental growth factor, part of 
the VEGF family, is well-known to be decreased in circulation of preeclamptic women, 
thus causing reduced activation of its receptors and subsequent diminished NO and 
prostacyclin stimulation (Yang et al., 2001; Maynard et al., 2003). VEGF inhibition has 
been documented to result in hypertension and proteinuria in clinical trials of cancer 
treatment (Yang et al., 2011).  
sFlt-1. In addition to decreased circulating VEGF, excess soluble fms-like 
tyrosine kinase-1 (sFlt-1) in placental tissue and amniotic fluid has been measured in 
preeclamptic pregnancies (Maynard et al., 2003).  sFlt-1 is a soluble receptor for VEGF  
that is increased in preeclampsia and antagonizes circulating VEGF and placental growth 
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factor (PlGF), another pro-angiogenic vasodilatory factor reduced in preeclampsia, to 
prevent VEGF interaction with membrane-bound receptors. sFlt-1 may be cleaved from 
Flt-1 to exclude the transmembrane domain or it may occur as a splice variant.  
Overexpression of sFlt-1 results in hypertension, endothelial dysfunction, and proteinuria 
(Maynard et al., 2003).  Adjusting this imbalance in pro- and anti-angiogenic factors may 
be key to managing symptoms of preeclampsia. 
Immune factors. The immune system is heavily implicated in the pathogenesis of 
preeclampsia.  In normal pregnancy, immune responses are heightened to prevent fetal 
rejection, but excessive immune activation occurs in preeclampsia and HELLP syndrome.  
The complement activation products C3a, C5a, and Bb are elevated in preeclampsia 
(Vinatier et al., 1995; Lynch et al., 2011, Lynch et al., 2008), and increased circulating 
complement component 3 is associated with hypertension in humans (Engström et al., 
2007). Preeclampsia is also a state of heightened systemic inflammation as evidenced by 
an increase of a number of inflammatory markers, including tumor necrosis factor (TNF)-
α, interleukin (IL)-6, and CD4+ T cells (Dekker et al., 1999). 
 
Certain risk factors, such as an observed increase in anti-angiogenic factors like 
sFlt-1, may predict the onset of preeclampsia and the presence of these risk factors may 
impact the severity of maternal and neonatal outcomes (Uzan et al., 2011; Ahmed, 2011). 
Other risk factors include obesity, ethnicity, compromised immunity, and excessive 
activation of C-reactive protein in response to inflammatory stimuli (Wolf et al., 2001; 
Cunningham et al., 2009).  Uric acid has been shown to inhibit trophoblast invasion and 
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endothelial cell apoptosis due to its antioxidant effects (Bainbridge et al., 2009) and 
hyperuricemia has been evident in women that subsequently develop preeclampsia. 
Though a wide spectrum of predictive factors has been identified, none have 
demonstrated promise as a feasible target for treatment and the only effective resolution 
for preeclampsia remains delivery of the placenta and concurrent birth.  Various 
pharmacological treatments (i.e. dietary antioxidants (Wang et al., 2011), calcium (Vest 
et al., 2012), aspirin (Powers et al., 2010), magnesium sulfate to discourage onset of 
seizures (Vest et al., 2012; LaMarca et al., 2011)) for preeclampsia have been postulated 
to encourage gestation to reach full-term, but none have proven entirely successful, and 
testing the utility of these treatments is ethically complicated.  Thus, various animal 
models mimicking symptoms of preeclampsia have been characterized and may be used 
to assess the viability of numerous management strategies.  
 
Animal models of preeclampsia 
Several effective animal models have been developed to study the pathogenesis 
and clinical manifestations of preeclampsia and potential treatment options therein 
(Sunderland et al., 2010). Though no single model fully encompasses all aspects of the 
condition, certain models may be utilized to target specific clinical symptoms or examine 
the role(s) of factors implicated as important in the onset or progression of the condition, 
as in genetically modified animal models. The most relevant models include the 
symptoms central to preeclampsia—hypertension and proteinuria.  These symptoms have 
been observed in models using placental ischemia (Alexander et al., 2001; Li et al., 
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2012), autoantibodies (Wallukat et al., 1999), overexpression of sFlt-1 in the rat 
(Kumasawa et al., 2011; Maynard et al., 2003), sFlt-1 infusion (Bridges et al., 2009; 
Murphy et al., 2011), complement component deficiencies (C1q-deficient C1q-/- (Singh, 
2011) or Crry-/- mice (Molina, 2005)), and vasoconstriction through nitric oxide 
inhibition (Yallampalli & Garfield, 1993; Molnár et al., 1994). 
Autoantibodies to angiotensin II type 1 receptor (AT1-AA) have been 
demonstrated to serve as a precursor to endothelial dysfunction in rat cardiomyocytes 
(Wallukat et al., 1999), a central characteristic of preeclampsia.  Infusion of AT1-AA in 
pregnant mice resulted in hypertension, proteinuria, and glomerular endotheliosis (Li et 
al., 2012), and AT1-AA infusion during the third trimester in pregnant rats led to 
hypertension, increased plasma sFlt-1, increased placental and renal endothelin-1, and 
oxidative stress (Li et al., 2012).  AT1-AA may be involved in induction of oxidative 
stress through generation of reactive oxygen species (ROS) through nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase and are also capable of stimulating sFlt-1 
production in the trophoblast (Wallukat et al., 1999; Zhou et al., 2008). These effects are 
evident in AT1-AA animal models (Herse & LaMarca, 2013). Additionally, AT1-AA has 
been demonstrated to lessen the invasive nature of trophoblastic cells and may be 
involved in abnormal pseudovasculogenesis (Zhou et al., 2008).  Interestingly, the 
cardiovascular effects observed with AT1-AA in pregnancy occur to a much lesser 
degree in a non-pregnant animal, indicating that the state of pregnancy is more sensitive 
to disruptions in autoantibody concentrations. AT1-AA had no effect on sFlt-1 
concentrations in non-pregnant animals. 
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Elevated levels of circulating sFlt-1 are observed in preeclampsia, and previous 
studies have shown that inducing overexpression of sFlt-1 in murine models causes 
hypertension, proteinuria, and endothelial dysfunction in pregnant animals (Alexander et 
al., 2004; Kumasawa et al., 2011). This phenotype is greatly exacerbated in the absence 
of eNOS in non-pregnant eNOS-/- mice (Li et al., 2012).  sFlt-1 is known to be secreted 
by the ischemic placenta (Gilbert et al., 2007; Makris et al., 2006), and placental ischemia 
is also associated with decreased glomerular filtration rate, renal plasma flow, and renal 
nitric oxide synthase seen in preeclampsia (Gilbert et al., 2010; Alexander et al., 2001). 
Maynard et al (2003) demonstrated that overexpression of sFlt-1 produced hypertension 
and glomerular endotheliosis in both pregnant and non-pregnant rats, indicating that sFlt-
1 acts on the maternal endothelium apart from the placenta, perhaps through its 
antagonism of VEGF (the prominent measurable vasodilator in the rat) and placental 
growth factor (PlGF).  PlGF is a pro-angiogenic homolog of VEGF that is the prominent 
vasodilator in humans. Thus, excessive circulating sFlt-1, whether originating 
endogenously from an ischemic placenta or administered exogenously, contributes to the 
preeclamptic phenotype in murine models. 
Various immune factors have been manipulated in murine models to produce a 
preeclamptic-like condition.  Mice deficient in the complement component 1q (C1q) 
develop hypertension, proteinuria, angiogenic imbalance of VEGF and sFlt-1, and 
endotheliosis (Singh et al., 2011).  Preeclamptic symptoms including hypertension and 
proteinuria, and characteristics such as endothelial damage also result with infusion of 
inflammatory markers into pregnant rats, such as tumor necrosis factor (TNF)-α 
  11 
(Alexander et al., 2002), interleukin (IL)-6, and CD4+ T cells (Li et al., 2012), 
implicating the relevance of the immune system in the pathophysiology and perhaps 
pathogenesis of preeclampsia. 
 
Reduced utero-placental perfusion pressure model of preeclampsia 
Though elevated levels of sFlt-1, AT1-AA, and inflammatory components are 
associated with symptoms of preeclampsia, it is not established that these factors are 
involved in its onset.  Placental ischemia, however, is a known precursor to preeclampsia 
due to abnormal spiral artery remodeling and models have been developed that 
mechanically reduce blood supply to the placentae, and these models successfully induce 
symptoms of preeclampsia, including hypertension and proteinuria. 
Reduced utero-placental perfusion pressure (RUPP) has been used in the dog, rat, 
rabbit, sheep, and non-human primate and results in a 20-80% decrease in arterial 
perfusion of the uterus in the pregnant animal (Li, 2012) and mimics early-onset 
preeclampsia (Gilbert et al., 2007).  The rat is a useful instrument in studying pregnancy 
because its trophoblast invasion is similarly deep to that of humans (Caluwaerts et al., 
2004).  In the rat, silver clips are placed on the lower abdominal aorta (ID 0.203 mm) 
superior to the iliac bifurcation and on both uterine arteries (ID 0.100 mm) to prevent any 
compensatory increase in blood flow to the uterus (Figure 1).  This partial obstruction of 
blood flow results in a suite of physiological changes that closely represent the 
preeclamptic phenotype. Features observed in the rat RUPP model include hypertension, 
proteinuria, decreased glomerular filtration rate (renal dysfunction), decreased renal 
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plasma flow, and increased vascular reactivity (Li et al., 2012).  Additionally, the RUPP 
procedure results in increased vasoconstriction evidenced by increased contractility of 
isolated renal arterial smooth muscle cells in response to angiotensin II (Murphy et al., 
2003).  Alterations in vasoactive substances contribute to this response, such as decreases 
in vasodilatory factors (i.e. VEGF, PlGF) and increases in vasoconstrictive factors (i.e. 
increased AT1-AA, sEng, ET-1 (LaMarca et al., 2008)).  Studies using heparin have 
reported increases in sFlt-1 in the RUPP model, but recent experiments in the RUPP 
model (Lillegard et al., 2013) and in humans (Searle et al., 2011) have demonstrated no 
increase in sFlt-1 in the absence of heparin, suggesting the hypertension caused by the 
RUPP procedure is independent of an increase in circulating sFlt-1.  Certain 
inflammatory cytokines (i.e. TNF-α (LaMarca et al., 2008), IL-6 (LaMarca et al., 2011) 
and oxidative stress (measured by 8-isoprostane and malondialdehyde) are also known to 
increase in the rat RUPP model, thus contributing to hypertension.  Pups of dams that 
undergo the RUPP procedure are documented to develop intrauterine growth restriction, 
though their placentation occurs normally.  
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Figure 1. The Reduced Utero-placental Perfusion Pressure (RUPP) model of placental 
ischemia.  On gestational day 14 of a 21-day term, silver clips are placed on the lower 
abdominal aorta (ID 0.203 mm) and on both uterine arcades (ID 0.10 mm) to induce 
placental ischemia, resulting in hypertension on gestational day 19.  Illustration modified 
from Even, M et al; J. Reprod. Fert. (1992) 96, 709-716. 
 
The RUPP model in the rat does not fully mimic human preeclampsia.  As 
aforementioned, placentation in the rat occurs normally, so studies using this model must 
focus on the physiology of symptoms occurring after the onset of placental ischemia.  
RUPP rats do not exhibit glomerular endotheliosis, which is an important characteristic 
of preeclampsia (Conrad et al., 2009).  The presence of proteinuria is inconsistent in the 
RUPP model (Granger et al., 2006) and this may be due to the short period of elevated 
blood pressure and altered angiogenic balance (JS Gilbert, Personal Communication).  
However, these limitations do not hinder the utility of the RUPP model in exploring 
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possible management or treatment options to manage hypertension, prolong gestation and 
promote maternal and perinatal health. 
A study by Gilbert et al. (2010) demonstrated that VEGF infusion attenuated 
hypertension and restored impaired glomerular filtration rate and endothelial dysfunction 
in rats with reduced uterine perfusion in a dose-dependent manner.  Furthermore, VEGF-
antagonism treatments used to control tumor growth may result in the development of 
hypertension in non-pregnant patients (van Heeckeren et al., 2007). These data indicate 
that VEGF plays a critical role in the hypertension following preeclampsia (Figure 2).  
Other studies of exogenous VEGF administration in experimental models have shown 
beneficial effects on renal recovery time (Masuda et al., 2001; Kim et al., 2000) and 
attenuation of post-cyclosporin A-induced nephropathy, hypertension, and endothelial 
dysfunction (Kang et al., 2001).  Furthermore, inhibition of VEGF activity has yielded 
several important results, such as increased apoptosis and proteinuria and decreased 
glomerular capillary repair in a rat model of mesangioproliferative nephritis (Ostendorf et 
al., 1999).  VEGF activity at its receptors is also known to contribute to increased 
superoxide dismutase expression (an enzyme critical for NO formation) and endothelial 
NO synthesis (Maynard et al., 2003), so decreased VEGF may result in dampened NO 
synthesis leading to decreased vasodilation.  
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Figure 2. Role of free VEGF in placental ischemia-induced hypertension. Placental 
ischemia precedes an increase in Flt-1/sFlt-1, which consequently decreases bioavailable 
VEGF. Decreased free VEGF leads to an increase in reactive oxygen species and 
decrease in NO to result in vascular dysfunction and hypertension. VEGF infusion 
attenuates hypertension associated with placental ischemia. 
 
Pravastatin, a commonly used inhibitor of a cholesterol-forming enzyme, has been 
examined in numerous animal models of preeclampsia. Singh et al (2011) utilized 
pravastatin in complement-deficient mice that reversed hypertension and induced 
placental growth factor (PlGF) expression to ameliorate endothelial dysfunction.  
Pravastatin has also been used to attenuate oxidative stress and hypertension in RUPP 
rats (Bauer et al., 2013) and preeclamptic symptoms in pregnant rats with overexpressed 
sFlt-1 (Saad et al., 2013; Fox et al., 2011; Kumasawa et al., 2010).  
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Certainly, novel therapeutic strategies are urgently needed to manage 
preeclamptic symptoms and promote maternal and fetal health for the full gestational 
term.  Thus, unique avenues must be explored to cover the spectrum of 
pathophysiological outcomes associated with preeclampsia.  VEGF is important to 
hypertension in preeclampsia and is associated with complement; Singh et al. (2011) 
demonstrated that complement-deficient mice exhibited a preeclamptic phenotype with 
increased blood pressure and decreased circulating VEGF. Because complement 
activation is increased in women with preeclampsia, we have focused on the complement 
system as a potential therapeutic target in managing preeclampsia.   
 
The complement system 
The immune system is a highly complex network of specialized cells and proteins 
critical to an organism’s defense against pathogenic invasion and infection.  There are 
two primary subsets of immunity: the adaptive immune system and the innate immune 
system.  The adaptive immune system is a delayed but specific response that involves 
various effector cells (B cells and T cells) capable of targeting pathogens expressing 
foreign (“non-self”) antigens.  The innate system is an immediate response that is non-
specific and recognizes foreign or invasive bodies.  The innate system initiates 
inflammation through various leukocytes and induces the adaptive response (i.e. antibody 
production from B cells and immune response trafficking or direct damage from T cells).  
Activated leukocytes release chemotactic substances to recruit these specialized effector 
cells, and the innate response heavily dictates the subsequent adaptive response (Le Bon 
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et al., 2002).  The complement system is a central component of the innate immune 
system that functions to eliminate infection and pathogenic invasion, opsonize antigens 
for phagocytic uptake, regulate the adaptive immune response, and mediate 
inflammation.   
 
Activation of the complement system 
Various circulating plasma proteins comprise the complement system and are 
synthesized mainly in hepatocytes and macrophages, though some production may occur 
in endothelial cells, fibroblasts, and monocytes.  Activation of the complement cascade 
can occur through various stimuli and different stimuli induce activation of one of three 
pathways: classical, lectin, or alternative.  Once activated, each pathway produces a series 
of enzymatic cleavage products to form the membrane attack complex through the 
terminal lytic pathway, which creates a pore in the cell membrane to ultimately lyse the 
invading organism (Figure 3). 
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Figure 3. Complement activation cascade.  Activation of the complement system initiates 
a cascade of enzymatic and proteolytic cleavage and synthesis events leading to the 
formation of the membrane attack complex, which is responsible for disrupting the 
cellular membrane of the invader and cell lysis. 
 
 Classical pathway activation occurs in response to antigen binding with antibody.  
Binding of the C1qr2s2 complex to IgG or IgM results in activation to a C1 esterase, 
which initiates cleavage of C4.  Once C4 is cleaved, the C4b fragment can covalently 
bind to surfaces to act as an opsonizing agent.  C4b interacts with C2, which is cleaved 
by C1s to form the classical pathway C3 convertase C4b2a. 
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 The lectin pathway is activated by polysaccharides common to many bacteria that 
bind to mannose-binding lectin (MBL) and ficolins.  MBL-associated serine proteases 
(MASP-1 and MASP-2) interact with these compounds to cleave C4 and C2 and thus 
form the classical pathway C3 convertase C4b2a apart from C1. 
 Alternative pathway activation is initiated by a number of foreign surfaces, 
including those of zymosan, endotoxin, and pure carbohydrates.  This pathway involves a 
different set of proteins that activate after C3 molecules spontaneously change to allow 
hydrolysis of the C3 thioester bond. The new C3 H2O compound binds to Factor B, 
which is then cleaved by Factor D to form the unstable C3 convertase, C3bBb.  Properdin 
(P) stabilizes the convertase. 
 Central to all three pathways is the formation of the C3 convertase (C4b2a, 
classical pathway; C3bBbP, alternative pathway), which is responsible for cleaving C3.  
Amplification of the system occurs with the formation of the C3 convertase due to its 
ability to cleave multiple C3 molecules.  Cleavage of C3 yields two immediate products: 
C3a, a small molecular weight product that remains in circulation, and C3b, which 
covalently binds to surfaces.  C3b, like C4b, may interact with complement receptor 1 
(CR1) or its soluble fragment to opsonize and clear immune complexes, or it may further 
the complement cascade to form the membrane attack complex.  In order to further the 
complement cascade, C3b binds to the C3 convertase to form the C5 convertase 
(C4b2a3b, classical pathway; C3bBb3bP, alternative pathway) that enzymatically cleaves 
C5 into C5a and C5b.  C5a remains in circulation and mediates inflammatory responses.  
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C5b is the component critical for formation of the membrane attack complex (MAC), 
C5b-9, in the cell membrane.  
 Degradation of C3b results in a number of smaller fragments (C3bi, C3dg, C3d) 
that interact with Complement Receptors 1-4.  These receptors are located on many cell 
types, including primate red blood cells, neutrophils, monocytes, macrophages, 
eosinophils, follicular dendritic cells, B cells, and certain T cells.  Interactions at 
complement receptors result in inflammatory and protective responses, like host defense, 
signaling to cells of humoral immunity, and clearance of immune complexes. 
 Complement activation is inherently regulated by a number of fluid-phase and 
membrane-bound inhibitors that act before and after assembly of the convertase and 
during formation of the MAC.  Dysregulation or excessive activation of the complement 
cascade results in an overabundance of active complement cleavage products that have 
widespread effects, such as cell lysis and excessive activation of the complement 
components (resulting in a complement deficiency).  Complement deficiency in these 
cases may be protective, as demonstrated by Ioannou et al (2012) in a lupus-prone mouse 
model of ischemia/reperfusion injury. Various complement inhibitors have been 
developed to inhibit damaging consequences of excessive complement activation. 
 
C3a/C5a 
 C3a and C5a are complement activation products that bind to their specific 
receptors to manifest anaphylactic symptoms, such as chemotaxis, smooth muscle 
contraction, increased vascular permeability, and mast cell degranulation (Schraufstatter 
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et al., 2001; Ames et al., 1997; Hartmann et al., 1997).  They are responsible for the 
release of inflammatory mediators from white blood cells and their receptors are widely 
expressed.   
 C5a is a well-characterized and very potent inflammatory peptide (anaphylatoxin) 
that is known to cause platelet aggregation and recruit polymorphonuclear leukocytes 
(PMN) and stimulate their release of ROS to damage the unrecognized cell membrane 
(Arumugam et al., 2004).  In the event of high concentrations of ROS, the arachidonic 
acid pathway may shift to increase production of thromboxane (TX) A2 (Greer et al., 
1991).  TXA2, a product of cyclooxygenase and a mediator of vasoconstriction and 
platelet aggregation, is implicated as a mediator in the C5a/C5a-desArg-induced pressor 
response (transient increase in blood pressure) observed in guinea pig (Fraser et al., 1989) 
and the C5a/ C5a-desArg-induced transient hypotension in the rat (Proctor et al., 2009). 
Furthermore, these transient changes in blood pressure were normalized with the 
cyclooxygenase inhibitor indomethacin (Fraser et al., 1989; Proctor et al., 2009), 
indicating that TXA2 is important in the C5a-mediated vasoactivity.  
Like C5a, C3a is a potent anaphylatoxin and is important in cellular activation of 
mast cells, monocytes, PMN, and certain basophils (Petering et al., 2000).  Following 
complement activation, C3/C3a is approximately 15 times more concentrated in the 
plasma than C5/C5a (Feinberg, 2006).  C3a is involved in eosinophil (but not PMN) 
chemotactic functions and ROS release (DiScipio et al., 1999; Petering et al., 2000; 
Hartmann et al., 1997) and is known to play a role in modulating TNF-α and IL-1β 
synthesis (Takabayashi et al., 1996). Fischer et al (1999) demonstrated that C3a 
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contributes significantly to inflammation and immune regulation through IL-6 
modulation. C3a has also been shown to act directly on the microvasculature to cause 
vasoconstriction, vascular leakage, and platelet aggregation (Björk et al., 1985).  
Recombinant human C3a and C3a analog peptides produce a transient pressor response 
when injected intravenously in the rat (Proctor et al., 2009), and C3a has been observed 
to increase in the rat RUPP model of placental ischemia concurrent with hypertension 
(Lillegard et al., 2013). 
To determine the functions of C3a in various systems, synthetic analogs have 
been developed.  It has been shown that the highly conserved essential amino acid 
sequence for C3a-specificity is LGLAR (Petering et al., 2000), and the synthetic peptide 
WWGKKYRASKLGLAR possesses the same biological functions and cationic charge as 
native human C3a (Bellows-Peterson et al., 2012).  The peptide is an effective agonist of 
C3a at the C3a receptor (C3aR), and Proctor et al. (2009) demonstrated a bolus injection 
of this peptide induced a transient hypertensive response in the non-pregnant rat. 
 
Complement inhibitors 
 A number of complement antagonists and inhibitors have been identified and 
characterized. An exogenous soluble form of complement receptor 1 (sCR1) inhibits 
formation of the C3 and C5 convertases by displacing the C3b and C4b binding domains 
(Weisman et al., 1990; Katyal et al., 2004), thus preventing the formation of 
anaphylatoxins and the membrane attack complex.  sCR1 has proven beneficial in animal 
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models of preeclampsia (Lillegard et al., 2013) and ischemia/reperfusion injury and 
inflammation by reducing tissue damage (Arumugam et al., 2004).  
Recently, Burwick & Feinberg (2013) presented a case study providing evidence 
for the utility of specific complement component inhibition in managing preeclampsia 
and HELLP syndrome. C5 inhibition by eculizumab in a patient with HELLP syndrome 
resulted in amelioration of clinical symptoms and improved abnormal laboratory values 
of LDH, free hemoglobin-binding haptoglobin, aspartate aminotransferase, and platelet 
count, thus prolonging gestation 17 days.  These data suggest that preventing C5a and 
C5b-9 (MAC) may be beneficial in managing severe preeclampsia or HELLP syndrome. 
The C3a receptor (C3aR) has been implicated as a pathophysiological factor in 
various inflammatory conditions.  It is a G protein-coupled receptor with two distinctive 
features: a wide distribution throughout tissues and an exceptionally long (>170 aa) 
second extracellular domain (Ames et al., 2001). C3aR-/- mice demonstrated an increased 
susceptibility to LPS challenge, indicating the importance of the receptor in endotoxin-
induced septic shock (Kildsgaard et al., 2000).  Additionally, C3aR has been implicated 
as a contributor to allergic asthma; ovalbumin-sensitized guinea pigs lacking functional 
C3aR have a decreased bronchial reactivity when challenged with allergen (Regal & 
Klos, 2000).  Thus, efforts have been put forth to develop a selective antagonist for the 
C3aR. 
In 2001, Ames et al identified and optimized N2-[(2,2-diphenylethoxy)acetyl]-L-
arginine (SB290157) as a selective C3aR antagonist.  It is a competitive non-peptide that 
has been shown to block C3a-mediated receptor internalization and Ca2+ mobilization in 
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human, mouse, and guinea pig C3aR-labeled rat basophilic leukemia cells without 
disrupting C5aR activity (Ames et al., 2001).  SB290157 effectively inhibits C3a-
mediated chemotaxis in a human mast cell line known to express the C3aR and naturally 
respond to C3a chemotaxis, but did not affect these actions mediated by C5a.  SB290157 
also blocks the spasmogenic effects of C3a as evidenced by a dose-dependent decrease in 
rat caudal artery contractile response after stimulation and inhibits the C3a-mediated 
release of ATP from guinea pig platelets (Ames et al., 2001).  In an LPS-induced airway 
neutrophilia model in the guinea pig, C3aR antagonism with SB290157 resulted in a 
greatly reduced neutrophil recruitment.  Further, SB290157 attenuated edema in a rat 
model of adjuvant arthritis (Ames et al., 2001) and reduced oxidative stress-mediated 
tissue damage in a mouse model of cerebral ischemia (Mocco et al., 2006). 
Additional studies have established the utility of SB290157 in a number of 
inflammatory conditions.  As mentioned, the C3a analog peptide produced a transient 
hypertension in the rat, and Proctor et al. (2009) demonstrated that antagonizing the 
C3aR with SB290157 prevented the C3a peptide-mediated pressor response in the rat in a 
dose-dependent manner.  Using an acute rat model of ischemia/reperfusion, Proctor et al. 
(2004) demonstrated that C3aR antagonism resulted in amelioration of several key 
features of intestinal ischemia/reperfusion injury, including an increase in serum alanine 
transaminase indicative of liver damage, edema caused by increased vascular 
permeability, and damage to the mucosa.  However, in the same study, SB290157 itself 
produced a transient hypertensive response and neutropenia, mimicking the action of 
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intravenously-infused C3a to guinea pigs (Regal & Klos, 2000) and rats (Proctor et al., 
2009). 
Mathieu et al (2005) further investigated the specific cellular activity of 
SB290157 and revealed agonist activity of the compound in certain cellular systems. In 
rat basophilic leukemia cells expressing human C3aR, various concentrations of 
SB290157 decreased the C3a-induced calcium mobilization response in a dose-dependent 
manner, but the antagonist itself also stimulated calcium mobilization (Mathieu et al., 
2005).  Importantly, Mathieu et al. postulated that the agonistic effects of SB290157 may 
be attributable to receptor density and distribution; in cells with low receptor expression 
(i.e. guinea pig platelets), SB290157 has no agonist effects, but agonist properties were 
evident in systems with high receptor expression (Mathieu et al., 2005; Therien, 2005).  
Therefore, results using this compound should be carefully interpreted.  However, among 
the few developed C3aR antagonists, none have been identified to be more specific or 
potent (Ames et al., 2001).  SB290157 is currently the most promising C3aR antagonist 
available, and antagonism of the C3aR may offer some therapeutic promise in offsetting 
symptoms associated with inflammatory conditions. 
 
Complement in pregnancy/preeclampsia 
Pregnancy is a state of heightened innate immune function, complement 
activation, and inflammation in order to prevent rejection of the fetus.  In normal 
pregnancy, the absolute number and activation of leukocytes increase, while T cell 
function has been shown to be downregulated (Luppi, 2003).  Numerous studies have 
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demonstrated a correlation between immune-compromised women and incidence of 
preeclampsia (Vinatier et al., 1995), and preexisting inflammation (as in obesity) has 
been demonstrated as a risk factor for developing preeclampsia due to increased vascular 
polymorphonuclear leukocyte (PMN) infiltration (Lynch et al., 2011; Walsh, 2007).   
Complement components are increased in normal pregnancy and are further 
increased in preeclampsia (Denny et al., 2013; Haeger et al., 1992), and specifically 
early-onset preeclampsia (Lim et al., 2012), and the complement component 3 (C3) is 
increased in hypertension (Engström et al., 2007).  C3a, C5a, and Bb are increased early 
in gestation in women with preeclampsia (Lynch et al., 2011; Derzsy et al., 2013; Lynch 
et al., 2008) and the presence of placental C4d is associated with preeclampsia (Buurma 
et al., 2012).  Recently our group has demonstrated that general complement inhibition 
with exogenous soluble complement receptor 1 (sCR1) attenuates the hypertension seen 
in the rat RUPP model of preeclampsia (Lillegard et al., 2013).  Long-term general 
complement inhibition is not a viable therapeutic option since it places the mother and 
fetus at risk for infection, so it is necessary to determine which particular components of 
the cascade are critical to pregnancy-induced hypertension.   
SB290157 has been used in the angiotensin II type 1 receptor antibody mouse 
model of preeclampsia to decrease hypertension and proteinuria at a 30 mg/kg dose 
(Wang et al., 2012).  Antagonism of the C3aR also effectively blocked the increase in 
sFlt-1 and significantly increased small placental and fetal weights.  This study was the 
first to identify the utility of SB290157 in ameliorating symptoms of preeclampsia in a 
pregnant animal and indicated the importance of C3a-mediated activity in the 
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pathophysiology of preeclampsia in the presence of elevated antibody concentrations.  
Thus far, no investigations have explored C3aR antagonism or the activity of SB290157 
in the context of placental ischemia-induced hypertension. 
Given this information, we resolved to investigate the role of complement system 
activation in placental ischemia-induced hypertension, first using a general complement 
inhibitor, and then a specific complement receptor antagonist for the C3a receptor.  Our 
studies primarily focused on the effect of complement inhibition or antagonism on 
complement activity and blood pressure, and secondarily the effects on angiogenic 
factors and fetal and placental data.  We sought to identify whether complement 
activation directly influences blood pressure or mediates blood pressure through 
angiogenic factors.
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Rationale & hypothesis: Chapter 2 
Despite major advances in obstetric and perinatal care, preeclampsia remains incurable 
aside from delivery of the placenta.  Preeclampsia is a leading cause of death and 
morbidity for both mother and offspring, and premature delivery to attenuate maternal 
symptoms places the neonate at great risk for health complications.  Thus, novel 
strategies are urgently needed to manage the symptoms of preeclampsia and prolong 
gestation.  Excessive complement activation has been observed in women with 
preeclampsia. Placental ischemia is widely accepted as a critical precursor to 
preeclampsia, and complement deficiency in animal models is protective against 
ischemia/reperfusion injury. Vascular endothelial growth factor has recently been linked 
to complement activation in placental dysfunction in a mouse model of spontaneous 
miscarriage. By using the Reduced Utero-placental Perfusion Pressure (RUPP) model of 
placental ischemia in the rat, we can induce the symptoms of preeclampsia following 
onset of placental ischemia, including an increase in complement activation and the 
complement activation product C3a.  We hypothesize that complement activation is 
critical to placental ischemia-induced hypertension, and that broadly inhibiting 
complement activation with a soluble form of the endogenous complement receptor CR1 
(sCR1) will attenuate the hypertension caused by placental ischemia in RUPP rats (Figure 
4). 
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Figure 4. Hypothesis.  Placental ischemia leads to complement activation resulting in 
increased C3a, decreased VEGF, and ultimately hypertension. 
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The following work (Chapter 2) was published in Molecular Immunology, 2013 
Nov;56(1-2):91-7. 
Authors: Lillegard K. E., Johnson A. C., Lojovich S. J., Bauer A. J., Marsh H. C., Gilbert 
J. S. and Regal J. F. 
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Chapter 2 
Complement activation is critical for placental ischemia-induced hypertension in the 
rat 
Overview 
Preeclampsia is a major obstetric problem defined by new-onset hypertension and 
proteinuria associated with compromised placental perfusion. Although activation of the 
complement system is increased in preeclampsia compared to normal pregnancy, it 
remains unclear whether excess complement activation is a cause or consequence of 
placental ischemia.  Therefore, we hypothesized that complement activation is critical for 
placental ischemia-induced hypertension.  We employed the reduced utero-placental 
perfusion pressure (RUPP) model of placental ischemia in the rat to induce hypertension 
in the third trimester and evaluated the effect of inhibiting complement activation with a 
soluble recombinant form of an endogenous complement regulator, human complement 
receptor 1 (sCR1; CDX-1135).  On day 14 of a 21-day gestation, rats received either 
RUPP or Sham surgery and 15 mg/kg/day sCR1 or saline intravenously on days 14-18. 
Circulating complement component 3 decreased and complement activation product C3a 
increased in RUPP vs Sham (p<0.05), indicating complement activation had occurred.  
Mean arterial pressure (MAP) measured on day 19 increased in RUPP vs Sham rats 
(109.8±2.8 mmHg vs 93.6±1.6 mmHg).  Treatment with sCR1 significantly reduced 
elevated MAP in RUPP rats (98.4±3.6 mmHg, p<0.05) and reduced C3a production.  
Vascular endothelial growth factor (VEGF) decreased in RUPP compared to Sham rats, 
and the decrease in VEGF was not affected by sCR1 treatment.  Thus, these studies have 
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identified a mechanistic link between complement activation and the pregnancy 
complication of hypertension apart from free plasma VEGF and have identified 
complement inhibition as a potential treatment strategy for placental ischemia-induced 
hypertension in preeclampsia.   
Key Words:  pregnancy; hypertension; preeclampsia; complement; C3a; placental 
ischemia; vascular endothelial growth factor 
 
Abbreviations: 
MAP, mean arterial pressure 
RUPP, reduced utero-placental perfusion pressure  
sCR1, soluble complement receptor 1  
sFlt-1, soluble fms-like tyrosine kinase-1  
SNP, sodium nitroprusside  
VEGF, vascular endothelial growth factor 
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Introduction 
The pregnancy-specific condition preeclampsia is a leading cause of maternal and 
fetal morbidity and mortality (Steegers et al., 2010).  Preeclampsia is hallmarked by new-
onset hypertension (systolic blood pressure of >140 mmHg or a diastolic blood pressure 
of >90 mmHg) and proteinuria (>300 mg/L) over a period of 24 hours.  The initiating 
event of preeclampsia is unknown.  Inadequate trophoblast invasion is postulated to 
impair maternal spiral artery remodeling in the placenta that is necessary to accommodate 
increased blood flow required for pregnancy.  This impaired spiral artery remodeling 
results in placental ischemia, accompanied by imbalances in angiogenic factors including 
vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) 
(Baker et al., 1995; Maynard et al., 2008), oxidative stress (Hubel et al., 1999; Mistry et 
al., 2013), endothelial dysfunction (Gilbert et al., 2008) and inflammation with excessive 
complement activation (Lynch and Salmon, 2010).  The impaired placental perfusion 
leads to hypertension, proteinuria and intrauterine growth restriction of the fetus 
(Steegers et al., 2010). Although many factors have been identified as contributors to this 
condition, delivery of the placenta remains the only definitive treatment and new 
treatment strategies are needed. 
In pregnancy, maternal mechanisms are evoked to prevent an immune response 
against the fetus and involve both innate and adaptive immunity (Denny et al., 2013; 
Lynch and Salmon, 2010), including the complement system.  The complement system is 
an enzymatic amplification system composed of endogenous plasma proteins that 
normally operates at a low steady state.  The components are sequentially activated by 
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any of three pathways (classical, lectin, and alternative) to function in host defense and 
inflammation and lead to pathogen opsonization (targeting for destruction) and/or lysis.  
Central to all three pathways is formation of a C3 convertase that cleaves complement 
component 3 (C3) into C3a, a fluid phase inflammatory product, and C3b, a larger 
fragment that covalently binds to surfaces and is an essential part of the enzyme C5 
convertase. Cleavage of C5 into C5a and C5b by C5 convertase can lead to formation of 
membrane attack complex, C5b-9, and lysis of the target. In uncomplicated pregnancies, 
a heightened inflammatory state is evident with the cleavage product C3a normally 
increasing in circulation as gestation progresses (Lynch and Salmon, 2010) and the acute 
phase protein C3 increasing (Baines et al., 1974).  
Regulation of this complement activation is important for a successful pregnancy 
as demonstrated by the inability of offspring to survive if mice lack the normal 
membrane-bound complement regulator Crry (Xu et al., 2000).  In addition, complement 
component C1q is necessary for normal placental development since C1q-deficient mice 
exhibit abnormal trophoblast migration and remodeling of spiral arteries and do not 
develop a normal placenta (Singh et al., 2011). In the rat, C3 synthesized in the uterus is 
necessary for normal fetal development and has been identified as an early post-
implantation embryotrophic growth factor (Usami et al., 2010).    
Though complement is necessary for a normal pregnancy, excessive activation of 
complement and generation of active fragments may be an important contributor to 
adverse pregnancy outcomes such as spontaneous miscarriage and preeclampsia.  In 
mouse models of spontaneous miscarriage and antiphospholipid syndrome, complement 
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activation product C5a is important in fetal loss and growth restriction (Girardi et al., 
2003; Girardi et al., 2006; Holers et al., 2002; Qing et al., 2011).  In preeclamptic 
pregnancies, elevated concentrations of complement activation products Bb, C3a and C5a 
have been observed both early in pregnancy as well as near term (Denny et al., 2013; 
Derzsy et al., 2010; Lynch et al., 2011; Lynch and Salmon, 2010).  It is unclear whether 
this excessive complement activation contributes to placental ischemia and/or placental 
ischemia causes complement activation and contributes to hypertension.  Since 
complement system activation has also been implicated in pathogenesis of 
ischemia/reperfusion injury in many different organs (Gorsuch et al., 2012) and the 
complement cleavage products C3a and C5a are vasoactive (Proctor et al., 2009; Regal 
and Klos, 2000), we hypothesized that complement activation occurs as a result of 
placental ischemia and leads to pregnancy-induced hypertension (Figure 4).  To test this 
hypothesis, we used the well-established reduced utero-placental perfusion pressure 
(RUPP) model of placental ischemia-induced hypertension in rat that mimics features of 
preeclampsia.  In the RUPP model, placental ischemia is induced in the third trimester of 
pregnancy resulting in a reduction in blood flow to the uteroplacental units and 
hypertension in the mother.  Our studies were designed to determine if complement 
system activation is increased due to placental ischemia in the RUPP model and to 
evaluate the effectiveness of complement inhibition using a soluble form of an 
endogenous complement regulator, soluble complement receptor 1 (sCR1), to attenuate 
hypertension seen in this model.  
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Materials and Methods 
Reduced utero-placental perfusion pressure (RUPP) procedure and sCR1 administration 
 The reduced utero-placental perfusion pressure (RUPP) procedure was employed 
to achieve chronic placental ischemia in the pregnant rat as described previously 
(Alexander et al., 2001; Crews et al., 2000; Gilbert et al., 2007a; Granger et al., 2006).  In 
brief, surgical procedures were performed with timed pregnant Sprague Dawley dams 
(Crl:CD IGS, Charles River Laboratories, Portage, MI) under isoflurane anesthesia.  All 
animal experiments were submitted to and approved by the University of Minnesota 
Institutional Animal Care and Use Committee and conformed to National Institutes of 
Health guidelines.  On day 14 of pregnancy, the jugular vein was cannulated and the 
cannula exteriorized to the back of the neck. Heparin was not used in cannulas due to its 
complement inhibitory properties, and a 25% dextrose lock solution was used to maintain 
cannula patency. For RUPP surgery under isoflurane anesthesia, a vertical midline 
incision was made, the lower abdominal aorta isolated and a sterile silver clip (0.203 mm 
ID) placed around the aorta above the iliac bifurcation.  This procedure reduces uterine 
perfusion pressure in the gravid rat by ~40%.  Since compensation of blood flow to the 
placenta occurs in pregnant rats through an adaptive increase in ovarian blood flow, both 
right and left uterine arcades are clipped at the ovarian end, right before the first 
segmental artery using a silver clip (0.100 mm ID).  All control dams underwent a sham 
operation, differing only in the absence of clips. sCR1 or saline vehicle (15 mg/kg/day in 
a volume of 2.6 ml/kg) was administered intravenously every 24 hours beginning 15-30 
min prior to RUPP or Sham surgery. Selected experiments used 30 mg/kg/day sCR1.  
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sCR1 (CDX-1135; Celldex Therapeutics, Needham, MA) was prepared under endotoxin-
free conditions, dialyzed against nonpyrogenic normal saline, and aliquoted and stored at 
-80°C. Rats were randomly assigned to one of four experimental groups based on 
surgical procedure and drug treatment: 1) RUPP surgery receiving a normal saline 
vehicle (RUPP Saline); 2) RUPP surgery receiving sCR1 (RUPP sCR1); 3) sham surgery 
receiving a normal saline vehicle (Sham Saline); 4) sham surgery receiving sCR1 (Sham 
sCR1).  
Measurement of mean arterial pressure and tissue collection 
An intra-arterial carotid catheter was placed on gestation day 18 under isoflurane 
anesthesia for measurement of mean arterial pressure (MAP) in unanesthetized restrained 
animals on day 19 of gestation.   Serum, plasma, and carotid arteries were harvested on 
day 19 as described previously (Alexander et al., 2001; Gilbert et al., 2007a; Gilbert et 
al., 2007b; Gilbert et al., 2010).  The uterus was exteriorized, the total number of viable 
and resorbed pups counted and the pups and placentae of the right horn weighed to 
determine placental efficiency (fetal weight/placental weight).  From the left horn, select 
utero-placental units from the ovarian, middle, and cervical uterine regions were fixed in 
10% neutral buffered formalin for histological analysis.   
Complement measurements 
C3a.  Serum concentrations of C3a were measured by Western immunoblot as 
previously described for guinea pig C3a (Regal and Klos, 2000). The primary antibody 
used for immunodetection was IgG fraction of rabbit polyclonal antibody to the 9 
carboxy-terminal amino acids of rat C3a (Research Genetics, Inc., Huntsville, AL).  The 
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blot was probed with a 1:2,500 dilution of primary antibody followed by 80 ng/mL of 
goat anti-rabbit IgG coupled to horseradish peroxidase (Pierce, Rockford, IL). Images 
were acquired as described previously (Gilbert et al., 2012) using incubation with 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, 
Rockford, IL) for 5 minutes, image capture with FluoroChem camera (AlphaInnotech, 
San Leadro, CA), and pixel density quantification with Un-Scan-It Gel Analysis Software 
(Silk Scientific, Orem, UT). Dilutions of a standard pool of rat serum complement-
activated by yeast were used to construct a standard curve on each gel and a regression 
equation was used to calculate the relative amount of C3a in the unknown samples.  
Relative amounts of C3a in each sample were expressed as C3a units/µl based on signal 
intensity of 1 µl of standard pool of rat serum activated by yeast. 
C3 ELISA. C3 was determined as previously described for mouse C3 (Taktak and 
Stenning, 1992) with modifications for rat using goat anti-rat C3 IgG fraction (MP 
Biomedicals, LLC. Solon, OH) as the capture antibody and a peroxidase-conjugated goat 
IgG fraction to rat complement C3 antibody for detection (1:8,000, MP Biomedicals, 
LLC. Solon, OH).  The concentration of C3 in each sample was expressed relative to a rat 
serum standard with one C3 unit/µl representing the optical density of a 1:4,000 dilution 
of that standard. 
Total complement hemolytic activity.  The inverse dilution of serum that causes 
50% hemolysis of sensitized sheep erythrocytes (CH50) was determined as an indicator of 
total complement pathway function as previously described (Larsen et al., 2001).   
Carotid artery myography 
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Uncannulated carotids were excised during necropsy, cleaned of adipose tissue, 
and a 1-2 mm segment cut from each carotid for myography. Carotid segments were 
placed in Krebs-Henseleit buffer (Regal et al., 1980) in DMT system baths (Model 610M, 
Danish Myo Technology, Aarhus, Denmark), normalized to transmural pressure of 100 
mmHg, and equilibrated for 60 minutes with 3-4 washes of Krebs-Henseleit buffer as 
previously described (Gilbert et al., 2010). Segments were pre-contracted with 
thromboxane mimetic U46619 (5.7x10-7 M), followed by addition of half-log increments 
of acetylcholine (1.38x10-8 M to 4.14x10-4 M) to assess endothelial-dependent relaxation.  
After washing, vessels were again contracted with U46619 and relaxed in response to 
half-log doses of sodium nitroprusside (1.0x10-8 M to 1.12x10-3 M) to assess endothelial-
independent relaxation. Finally, after washing, a cumulative concentration response curve 
to U46619 verified vessel reactivity at the end of the experiment. 
Plasma VEGF and sFlt-1 assays 
Circulating free VEGF and sFlt-1 concentrations in EDTA plasma collected on 
day 19 of gestation were measured using commercially available kits for Mouse VEGF 
and Mouse sVEGF R1 from R&D Systems (Quantikine, Minneapolis, MN) according to 
manufacturer’s directions and as described previously (Gilbert et al., 2007b; Gilbert et al., 
2010).   
Statistical analyses 
Data are presented as mean or geometric mean ± SE, and differences were 
considered significant when p<0.05. Data were analyzed using two-way ANOVA with 
three individual contrasts considered most relevant for comparison of means:  Sham 
  40 
Saline vs RUPP Saline, RUPP Saline vs RUPP sCR1, and Sham Saline vs Sham sCR1. 
C3a, CH50 and VEGF values were logged to meet model assumptions.   
 
Results 
sCR1 significantly inhibits placental ischemia-induced increase in MAP  
MAP increased in RUPP Saline compared to Sham Saline dams (Figure 5).  15 
mg/kg/day sCR1 treatment on days 14-18 markedly attenuated the elevated MAP in the 
RUPP group with no difference between the two Sham groups.  Selected experiments 
were conducted using 30 mg/kg/day sCR1 on days 14-18 with a similar significant 
inhibition of MAP (p<0.05 vs RUPP Saline; RUPP sCR1 at 30 mg/kg MAP 100.3±4.6 
mm Hg).   
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Figure 5. sCR1 significantly inhibits placental ischemia-induced increase in mean 
arterial pressure (MAP). The increase in MAP in RUPP Saline (n=22) compared to Sham 
Saline rats (n=19) was significantly inhibited by daily iv administration of 15 mg/kg 
sCR1 (RUPP sCR1, n=9).  MAP did not differ between Sham sCR1 (n=6) and Sham 
Saline groups.  Values represent mean ± SE of MAP measured day 19 of gestation 
(term=21 days).  *p<0.05 for indicated comparisons. 
 
sCR1 inhibits placental ischemia-induced complement activation  
With excessive complement activation, the cleavage of C3 can outpace new 
synthesis of protein leading to reduced C3.  As seen in Figure 6, the RUPP procedure 
results in significantly decreased C3 in the circulation, suggesting excessive complement 
activation occurred and C3 substrate was being consumed.   To more directly assess 
complement activation and the effect of sCR1, C3a in circulation was determined.  
Placental ischemia induced a significant increase in C3a when compared to controls 
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(Figure 7).  However, sCR1 effectively inhibited this complement activation as evidenced 
by decreased C3a concentrations in RUPP sCR1 animals. As previously reported (Balta 
et al., 2011) and confirmed in our studies, RUPP surgery with clip placement in a non-
pregnant female rat did not increase blood pressure. In addition, C3a did not significantly 
change over a 5-day period in a non-pregnant female with RUPP surgery and clip 
placement (C3a change of 0.05±0.07 units/µl). 
The efficacy of sCR1 in inhibiting the complement system in vivo was also 
evaluated by measuring the ability of serum collected on gestation day 19 to lyse 
antibody-coated sheep erythrocytes via a total hemolytic complement assay. Total 
hemolytic complement activity was not different in RUPP Saline and Sham Saline 
groups, but treatment with sCR1 significantly decreased the CH50 in serum from both 
RUPP and Sham animals (Figure 8).  In fact, CH50 was significantly less in Sham sCR1 
animals compared to RUPP sCR1 animals suggesting that it was a more effective 
inhibitor in control animals. 
Placentae of RUPP and Sham animals were examined in all treatment groups by 
immunohistochemistry using a polyclonal anti-rat C3 antibody to determine if C3 
deposition was evident.  No difference in intensity or location of immunoreactive C3 was 
detected between the two groups (data not shown). 
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Figure 6.  Complement component C3 is reduced in serum obtained day 19 of gestation 
in RUPP Saline (n=10) compared to Sham Saline rats (n=12). Units of C3 are relative to 
a rat serum standard as described in Materials and Methods.  *p<0.05 vs Sham. 
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Figure 7.  sCR1 significantly inhibits placental ischemia-induced increase in C3a.  C3a 
concentrations increased in RUPP Saline (n=13) compared to Sham Saline dams (n=12).  
Treatment with 15 mg/kg/day sCR1 decreased C3a serum concentrations in both RUPP 
(n=5) and Sham (n=6) groups compared to RUPP Saline. Values represent geometric 
mean ± SE of C3a units/µl in serum obtained day 19 of gestation.  Units of C3a are 
relative to a standard pool of yeast activated rat serum as described in Materials and 
Methods.  *p<0.05 for indicated comparisons, #p<0.05 comparing Sham Saline to Sham 
sCR1.
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Figure 8.  Treatment with 15 mg/kg/day sCR1 for 5 days significantly reduced CH50 in 
serum of RUPP and Sham animals.  The CH50 in RUPP Saline (n=12) and Sham Saline 
(n=12) groups were not different.  Treatment with sCR1 significantly decreased CH50 in 
serum collected on day 19 from RUPP sCR1 (n=5) and Sham sCR1 (n=6) compared to 
controls. Values represent geometric mean ± SE of CH50 in serum collected day 19 of 
gestation.  *p<0.05 for indicated comparisons, #p<0.05 comparing Sham Saline to Sham 
sCR1.  Sham sCR1 vs RUPP sCR1 was also tested for this outcome and was statistically 
different, p<0.05. 
 
sCR1 does not affect the VEGF decrease observed in placental ischemia 
Hypertension following placental ischemia is associated with a decreased free 
plasma VEGF and increased sFlt-1, and infusion of VEGF attenuates placental ischemia-
induced hypertension (Gilbert et al., 2010).  No increase in circulating sFlt-1 was 
observed in RUPP vs Sham (118.4±19.4 pg/mL vs 114.9±20.4 pg/mL) with measured 
values near the detection limit of the assay.  VEGF significantly decreased with placental 
ischemia (Figure 9) and no restoration of VEGF was evident in RUPP animals with sCR1 
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treatment.  The sFlt-1/VEGF ratio did not differ amongst treatment groups (data not 
shown). 
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Figure 9.  sCR1 treatment did not reverse RUPP-induced decrease in free VEGF 
concentrations in plasma. RUPP Saline animals (n= 21) had a decrease in VEGF 
compared to Sham Saline animals (n= 19). VEGF concentrations did not change in RUPP 
sCR1 animals (n=9) compared to RUPP Saline animals.  Concentration of VEGF did not 
differ in Sham Saline and Sham sCR1 (n=6) animals.  Values represent geometric mean ± 
SE of free VEGF measured by ELISA in plasma obtained from animals day 19 of 
gestation.  *p<0.05 for indicated comparisons. 
 
 
sCR1 alters endothelial-independent arterial relaxation  
The contractile response to submaximal concentration of thromboxane mimetic 
U46619 did not differ between RUPP and Sham animals.  The RUPP procedure did not 
significantly alter endothelial-dependent acetylcholine-induced relaxation of the carotid 
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artery (Figure 10A).  Histological analysis of select vessels clearly showed intact 
endothelium.  Dilation in response to the endothelial-independent vasodilator sodium 
nitroprusside (SNP) was also not altered in RUPP compared to Sham (data not shown). In 
carotid arteries from either RUPP or Sham animals treated with sCR1, the vasodilatory 
response to SNP was enhanced (Figure 10B) with no effect on acetylcholine-induced 
relaxation (data not shown). sCR1 itself did not relax an isolated carotid artery from a 
pregnant animal or cause relaxation of an artery pre-contracted with U46619 (data not 
shown).  In addition, presence of sCR1 in the myography bath did not significantly alter 
vasodilation to either acetylcholine or SNP in carotid artery from a normal pregnant rat 
(data not shown).   
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Figure 10.  Effect of placental ischemia and sCR1 on relaxation responses of carotid 
artery in vitro.  Values represent mean ± SE of the fraction relaxation of arteries pre-
contracted with thromboxane mimetic U46619.  A.  Carotid arteries isolated from RUPP 
Saline (n=16) or Sham Saline (n=13) animals relaxed to increasing concentrations of 
acetylcholine with no significant treatment effect.  B. sCR1 enhances endothelial-
independent relaxation in carotid arteries isolated from RUPP and Sham animals.  
Carotid arteries isolated from animals either treated with saline or sCR1 were pre-
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contracted with U46619 and the fraction relaxation to increasing concentrations of 
sodium nitroprusside (SNP) determined.  *Repeated measures ANOVA demonstrated a 
significant sCR1 effect in carotid arteries from RUPP and Sham animals. Values 
represent geometric mean ± SE of 6-16 animals is each group. 
 
sCR1 does not affect the RUPP-induced increase in fetal resorptions 
Fetal resorptions were significantly increased in RUPP Saline and RUPP sCR1 groups 
compared to Sham Saline or Sham sCR1 groups with no significant sCR1 treatment 
effect (Figure 11). Neither average placental weights nor placental efficiencies (fetal 
weight/placental weight) were significantly different amongst any of the treatment groups 
(data not shown). 
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Figure 11.  sCR1 treatment did not affect RUPP-induced fetal resorptions. RUPP Saline 
animals (n= 22) had an increase in resorptions compared to Sham Saline animals (n= 19). 
The fraction of fetal resorptions did not change in RUPP sCR1 animals (n=9) compared 
to RUPP Saline animals.  Values for Sham Saline did not differ compared to Sham sCR1 
(n=6). Values represent mean ± SE of the fraction of resorbed fetuses on day 19 of 
gestation.  *p<0.05 for indicated comparisons. 
 
Discussion 
Our studies are the first to demonstrate that inhibition of complement activation 
attenuates development of high blood pressure following placental ischemia in 
pregnancy, indicating that complement activation is a critical event leading to placental 
ischemia-induced hypertension. Using the RUPP model, we established that complement 
activation occurs in concert with placental ischemia-induced hypertension and that sCR1 
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effectively inhibits complement activation to attenuate this hypertension.  Previous 
studies had indicated an important role for angiogenic imbalance in mediating the blood 
pressure increase (Gilbert et al., 2010), but inhibition of complement activation 
attenuated placental ischemia-induced hypertension regardless of concurrent decreases in 
free plasma VEGF. These studies provide evidence for an important pathway leading to 
hypertension distinct from angiogenic imbalance and highlight the potential utility of 
inhibiting complement activation to manage hypertension in pregnancy.  
 Numerous mediators have been implicated in the pathogenesis of pregnancy-
induced hypertension including TNFα, sFlt-1, endothelin, oxidative stress, CD4+ T cells 
and agonistic autoantibody to angiotensin II type 1 receptor (Li et al., 2012). Many 
animal models of preeclampsia have been described using a single mediator as a discrete 
initiating event leading to symptoms of preeclampsia. However, preeclampsia is a 
heterogeneous disorder with varying degrees of angiogenic imbalance and autoantibody 
production, so we chose to use a model that employs placental ischemia as the initiating 
event for the wide range of characteristics that mimic preeclampsia to determine the role 
of complement system activation.  Placental ischemia is a consistent finding in 
preeclampsia and does not presume the mechanistic pathways leading to the 
hypertension. In addition, placental ischemia as the initiator of hypertension allows 
concurrent inflammatory and angiogenic pathways to operate in situ resulting in 
hypertension. The RUPP procedure is an established and effective means of inducing 
hypertension following placental ischemia in animal models and closely mimics many 
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characteristics of preeclampsia (Li et al., 2012) without inducing symptoms of severe 
preeclampsia (Balta et al., 2011). 
During pregnancy, complement activation has been implicated in pathogenesis of 
hypertension in two different studies in mice; abnormal placental development (C1q 
deficiency) or infusion of autoantibody to angiotensin II type 1 receptor.  The C1q-
deficient model investigates events leading to placental ischemia as well as resulting from 
placental ischemia. Mice deficient in C1q exhibit abnormal placental development during 
pregnancy resulting in preeclamptic symptoms including high blood pressure. Thus C1q 
early in pregnancy is essential for normal placentation and to maintain normal blood 
pressure throughout pregnancy (Singh et al., 2011). In third trimester pregnant mice with 
the placenta already formed, adoptive transfer of human autoantibodies to the angiotensin 
II type I receptor  (AT1-AA) results in symptoms resembling preeclampsia including 
increased blood pressure.  A C3a antagonist prevents the AT1-AA-induced hypertension 
indicating that excessive complement activation during pregnancy mediates hypertension 
initiated by the immune complex formation of AT1-AA with its receptor (Wang et al., 
2012; Zhou et al., 2008).  Whether complement activation following placental ischemia 
involves AT1-AA is a subject of future investigations. 
Inhibition via sCR1 targets complement activation products C3b and C4b to 
promote their degradation and accelerate decay of convertase enzymes in the complement 
cascade.  sCR1 has been extensively used to assess the importance of complement system 
activation in numerous rodent models of autoimmune and inflammatory diseases 
(Goodfellow et al., 1997; Piddlesden et al., 1994) and was clearly effective in inhibiting 
  52 
both C3a production and resultant hypertension in the RUPP model. The sCR1 reduction 
in CH50 at day 19 was significant but not as marked as some previously published studies. 
sCR1 effectiveness in inhibiting total hemolytic complement activity may be limited by 
the 5 day treatment course in our study, consistent with the observations made by Pratt et 
al (Pratt et al., 1997) who demonstrated rat anti-human sCR1 antibody production after 
several days that limits effectiveness.  sCR1 is also known to bind C1q (Klickstein et al., 
1997) and MBL (Ghiran et al., 2000) and thus may affect processes beyond inhibition of 
the complement cascade at the level of the C3 and C5 convertases. In our rat studies, 
sCR1 treatment does not begin until day 14 of gestation so any possible effects on C1q 
would be restricted to those occurring after placentae are established.   Our studies 
address the role of complement activation downstream of placental ischemia as opposed 
to the previously reported role for complement upstream of placental ischemia in a C1q-
deficient mouse (Singh et al., 2011).  
Clearly, inhibition of complement activation has the potential to increase 
susceptibility to infection and limits its usefulness for long term therapy.  Any human use 
of sCR1 or other complement inhibitors would employ appropriate immunizations and 
close monitoring similar to that used with the anti-C5 antibody eculizumab for treatment 
of paroxysmal nocturnal hemoglobinuria (Kelly et al., 2010).  A recent case report using 
eculizumab in a woman with preeclampsia/HELLP syndrome successfully normalized 
lab values and prolonged pregnancy by 17 days suggesting that therapeutic manipulation 
of the complement system during pregnancy may be feasible (Burwick and Feinberg, 
2013).  
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Data from previous investigations show significant changes in circulating pro- 
and anti-angiogenic factors following the RUPP procedure; specifically, RUPP rats 
exhibit decreased VEGF and increased sFlt-1 compared to Sham (Gilbert et al., 2007b; 
Gilbert et al., 2010).  A decrease in free plasma VEGF was apparent in our studies, but 
was not restored with sCR1 treatment, indicating that complement activation mediates 
hypertension regardless of changes in free plasma VEGF. This is in contrast to studies of 
fetal rejection and growth restriction in the mouse where inhibition of C5 resulted in an 
increase in plasma free VEGF and a decrease in sFlt-1 (Girardi et al., 2006).  In our 
study, inhibiting complement activation did not restore VEGF but attenuated 
hypertension introducing the possibility that low VEGF may result in increased 
complement activation. A recent report (Keir, 2012) suggests that decreased VEGF in the 
kidney might allow excessive complement activation to occur due to a decrease in 
complement regulators.     
Unlike other studies in the RUPP model, heparin was not used in our 
experimental protocol due to its demonstrated ability to inhibit complement activation 
(Girardi et al., 2004).  It is known that heparin treatment in coronary angiography results 
in elevated sFlt-1 and that sFlt-1 increases in the circulation of mice treated with heparin 
(Searle et al., 2011). In a recent abstract, heparin is also reported to displace sFlt-1 from 
rat placenta and increase circulating sFlt-1 (George, 2012). Thus, it is possible that the 
lack of increased circulating sFlt-1 in our study may be due to its continued sequestration 
in the placenta in absence of added heparin in the experimental protocol.  Regardless, 
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hypertension following placental ischemia was evident in the absence of changes in 
circulating sFlt-1.  
A difference in endothelial-dependent relaxation of aorta or carotid from RUPP 
rats vs Sham was not detected in our study suggesting that endothelial dysfunction of the 
larger blood vessels did not occur.  This is in contrast to the spectrum of impaired 
endothelial-dependent relaxation of carotid and aorta reported in Sprague Dawley rats 
obtained from Harlan following RUPP surgery (Crews et al., 2000; Gilbert et al., 2010).  
In light of previous findings that inhibition of NO synthase increases blood pressure more 
in Sprague Dawley rats from Harlan compared to Charles River, our data support the 
possibility of differences in the relative contribution of endothelium-derived NO to 
carotid artery function in Charles River rats compared to Harlan (Buhimschi et al., 2001; 
Pollock and Rekito, 1998).  In addition, more recent studies (Griffin et al., 2012) have 
also reported differences in nephropathy susceptibility and systemic and renal 
hemodynamic responses to the NO synthase inhibitor L-NAME in rats from the two 
suppliers.  Therefore, differences in the effect of the RUPP procedure on endothelial-
dependent relaxation may be due to strain differences in Sprague Dawley rats obtained 
from different distributors. Treatment with sCR1 in vivo resulted in greater carotid 
relaxation in both the RUPP and Sham groups in response to SNP, indicating 
complement may be acting independently of endothelium; however, sCR1 itself did not 
have direct effects on the vessel so further investigations are warranted.  
 Our data are first to demonstrate that inhibiting complement system activation 
may be a novel therapeutic strategy for managing hypertension following placental 
  55 
ischemia in preeclampsia.  Using a well-characterized and highly relevant model of 
preeclampsia in the rat, we have demonstrated a mechanistic link between complement 
activation and hypertension in pregnancy.  Our data suggest that placental ischemia, a 
consistent feature of preeclampsia, leads to complement activation and hypertension in 
the rat by a pathway distinct from VEGF. General complement inhibition may not be an 
optimal therapeutic strategy for preeclampsia, however, because of the potential 
increased risk of maternal and fetal infection.  Certainly, further research is necessary to 
identify how complement is activated following placental ischemia and to determine the 
complement activation product(s) (e.g. C3a, C5a, C5b-9) responsible.  
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Rationale & hypothesis: Chapter 3 
Inhibition of complement activation with sCR1 successfully attenuated placental 
ischemia-induced hypertension with no effect on free VEGF.  sCR1 itself is not a 
clinically preferred treatment because it abolishes the maternal innate response, 
potentially leaving the mother vulnerable to infectious agents.  Therefore, our goal was to 
identify the complement activation product that is key to placental ischemia-induced 
hypertension.  C3a is a potent anaphylatoxin that, when complement is activated, is 
approximately 15 times more concentrated than C5a in plasma.  Elevated C3 is associated 
with hypertension and increased C3a is documented in preeclampsia.  C3a is known to 
cause vasoconstriction, and acute administration of C3a produces a pressor response in 
the rat.  The C3a-induced pressor response is abolished with the competitive selective 
C3a receptor antagonist, SB290157, and a high dose of SB290157 has been shown to 
effectively abrogate angiotensin II type 1 receptor antibody-induced hypertension in a 
mouse model of preeclampsia.  Thus, we hypothesize that C3a is the complement 
activation product responsible for placental ischemia-induced hypertension, and that 
inhibiting the C3a/C3aR interaction with SB290157 will attenuate the hypertension 
caused by placental ischemia in RUPP rats (Figure 12).  Since no restoration of free 
VEGF occurred with sCR1-mediated complement inhibition, our working hypothesis is 
modified to include the possibility that complement and VEGF act independently to 
influence blood pressure in the rat model of placental ischemia-induced hypertension. 
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Figure 12. Hypothesis.  Placental ischemia leads to complement activation resulting in 
increased C3a that leads to hypertension.  SB290157 is a C3a receptor antagonist and we 
hypothesize that antagonizing the C3a receptor will attenuate hypertension mediated by 
C3a. Because general complement inhibition did not restore free VEGF concentrations, 
we now hypothesize that decreases in free VEGF may occur prior to complement 
activation or act in parallel to contribute to hypertension. 
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Chapter 3 
Effect of C3a receptor antagonism on placental ischemia-induced hypertension in 
the rat  
Overview 
 Preeclampsia remains one of the leading causes of maternal and perinatal 
morbidity and mortality in pregnancy.  Previous studies have established that the immune 
response is elevated in pregnancy, and excessive activation of the complement system, a 
component of the innate immune response, occurs in preeclampsia.  Our recent studies 
show that broadly inhibiting complement activation with soluble complement receptor 1 
(sCR1) attenuated placental ischemia-induced hypertension in the rat without affecting 
concentrations of pro-angiogenic vascular endothelial growth factor (VEGF), thus 
providing evidence for the importance of complement activation itself in pregnancy-
induced hypertension.  We then sought to identify which specific portion of the 
complement cascade was critical.  We hypothesized that C3a, a potent anaphylatoxin that 
is increased in preeclampsia, is essential to placental ischemia-induced hypertension.  We 
used the reduced utero-placental perfusion pressure (RUPP) model of placental ischemia-
induced hypertension in the rat and blocked the C3a receptor (C3aR) with the selective, 
competitive antagonist SB290157.  5 mg/kg SB290157 attenuated placental ischemia-
induced hypertension in the RUPP dams with no effect on the Sham group as measured 
by arterial catheter in unanesthetized rats.  Circulating free VEGF concentrations were 
not changed with SB290157, indicating the decrease in free VEGF occurs before or in 
parallel with complement activation.  SB290157 did not improve reduced fetal or 
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placental weights in the RUPP group.  Further, acute administration of a C3a analog 
peptide caused a pressor response in anesthetized, unrestrained pregnant and non-
pregnant rats, and 100 µg/kg SB290157 abolished this pressor response in both non-
pregnant and pregnant rats.  Thus, antagonism of the C3aR may offer some therapeutic 
benefit in managing hypertension in preeclampsia. 
  
Introduction 
Preeclampsia is a serious obstetric complication characterized by new-onset 
maternal hypertension and proteinuria.  Because preeclampsia is largely untreatable apart 
from parturition, it is a major cause of maternal and perinatal death.  New therapeutic 
strategies are urgently needed to manage the symptoms of this condition and thereby 
promote gestational success for mother and fetus. 
Though the definitive cause remains unknown, multiple factors are implicated in 
the pathogenesis and/or manifestation of gestational hypertension and preeclampsia.  
Imbalances in pro- and anti-angiogenic factors have been measured in women with 
preeclampsia, including a decrease in bioavailable pro-angiogenic vascular endothelial 
growth factor (VEGF) and an increase in circulating soluble fms-like tyrosine kinase-1 
(sFlt-1), the receptor for VEGF (Maynard et al., 2003).  In an animal model of placental 
ischemia, exogenous administration of VEGF attenuated placental ischemia-induced 
hypertension in a dose-dependent manner, suggesting that free VEGF is critical to blood 
pressure regulation during pregnancy (Gilbert et al., 2010). 
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In pregnancy, the immune response must be tightly regulated to prevent rejection 
of the fetus.  The immune response involves the adaptive immune system, which is 
comprised of differentiated lymphocytes and is responsible for a specific but delayed 
response, and the innate immune system, which enables an immediate but non-specific 
response.  The complement system is part of the innate immune system and is an 
enzymatic amplification system composed of plasma proteins.  Normally, the 
complement system operates at a low steady state and responds to heal or eliminate 
pathogenic infection. However, excessive activation of complement can be harmful, and 
increases in activation products (i.e. C3a, C5a, Bb) have been observed across a wide 
spectrum of conditions, and previous studies have shown that women with preeclampsia 
have elevated levels of complement activation products (Lynch et al., 2011).  In addition, 
there is evidence for an association between high concentrations of circulating 
complement component 3 (C3) and hypertension (Engström et al., 2007).  Studies using 
various animal models have shown that administration of complement activation products 
can increase blood pressure (Regal et al., 1980; Proctor et al., 2009), and our group 
recently demonstrated that inhibiting the complement cascade with soluble complement 
receptor 1 (sCR1) attenuated hypertension in the reduced uterine perfusion pressure 
(RUPP) model of placental ischemia-induced hypertension in the rat.  sCR1 did not 
restore the decrease in free VEGF in the RUPP model, indicating that complement 
activation does not influence the decrease in free VEGF, but changes in circulating 
VEGF levels may act in parallel to or occur before complement activation to affect blood 
pressure.   
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Activation of the complement system from various stimuli results in cleavage of 
the complement component 3 yielding C3a, an anaphylatoxin, and C3b, an opsonizing 
agent also critical to furthering the complement cascade to ultimately destroy the foreign 
body.  C3a is a small molecular weight product that is known to mediate inflammation 
and vascular smooth muscle contraction (Proctor et al., 2009).  Several reports have 
identified the direct roles of C3a in causing vessel contraction (Denny et al., 1978; Björk 
et al., 1985; Qu, 2009), vascular leakage, and platelet aggregation (Björk et al., 1985). It 
has also been shown to play a role in regulating tumor necrosis factor-α (Takabayashi et 
al., 1996), which affects endothelial cells through inflammatory mediators and reportedly 
contributes to pregnancy-induced hypertension (LaMarca et al., 2008).  C3a has been 
shown to be involved in modulating IL-6 to produce inflammation and further regulate 
immune responses (Fischer et al., 1999).  However, the physiological roles of C3a have 
not been thoroughly characterized.  
Previous studies have utilized exogenous C3a and/or C3a receptor (C3aR) 
agonists and antagonists to explore the hypertensive response in animal models (Bao et 
al., 2005; Wang et al., 2012; Proctor et al., 2009).  Intravenous injection of the C3a 
analog peptide WWGKKYRASKLGLAR, referred to hereon as C3a peptide, and 
recombinant human C3a (rhC3a) both result in a rapid and transient increase in blood 
pressure in a non-pregnant rat (Proctor et al., 2009).  The C3aR antagonist SB290157 is 
known to effectively inhibit C3a activity in vivo and in vitro by blocking C3a-induced 
calcium mobilization and receptor internalization in human neutrophils, and, importantly, 
by blocking a C3a-induced increase in muscular contractile response (Qu, 2009).  Proctor 
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et al. demonstrated that administration of SB290157 in the rat attenuated the increased 
blood pressure following complement activation by cobra venom factor (Proctor et al., 
2006) or C3a peptide (Proctor et al., 2009), and the compound itself induced neutropenia.  
These studies suggest that C3a is a putative mediator of hypertension, but thus far, no 
studies have examined the therapeutic potential of using a C3aR antagonist in pregnancy-
induced hypertension.  Therefore, we sought to identify C3a as an important product of 
complement system activation responsible for placental ischemia-induced hypertension. 
To test this, we used the C3a receptor antagonist, SB290157, which has been shown to 
have high efficacy and specificity for the C3aR in the rat (Ames et al., 2001).   
Studies have shown that acute administration of the C3a analog produced a 
transient hypertension and SB290157 blocked this response in a dose-dependent manner 
(Proctor et al., 2009), and we previously demonstrated that mechanically inducing 
ischemia in the placenta via the RUPP procedure results in increased circulating C3a and 
hypertension (Lillegard et al., 2013).  Thus, we hypothesize that C3a is an important 
factor in placental ischemia-induced hypertension and intrauterine growth restriction and 
SB290157 will attenuate hypertension in the pregnant rat by inhibiting the C3a-mediated 
hypertensive responses independent of VEGF (Figure 12). 
 
Materials & Methods 
Reduced utero-placental perfusion pressure (RUPP) procedure 
 The RUPP procedure was performed on gestational day 14 to achieve chronic 
placental ischemia in the pregnant rat on gestational day 19 as described in Chapter 2.  In 
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brief, timed pregnant Sprague Dawley rats from Charles River (approximately 250 g at 
time of shipment) were anesthetized with 2-3% isoflurane.  The jugular vein was 
catheterized and due to the effect of heparin on complement activation, a 25% dextrose 
lock solution was used to maintain catheter patency.  Silver clips were placed on the 
lower abdominal aorta superior to the iliac bifurcation and on the ovarian arteries 
between the ovaries and the first pup to induce placental ischemia. All animal 
experiments were submitted to and approved by the University of Minnesota Institutional 
Animal Care and Use Committee and conformed to National Institutes of Health 
guidelines.  
SB290157 preparation 
 SB290157 (Merck KGaA, Darmstadt, Germany) was suspended in 10% 
ethanol/saline to make a 5 mg/ml stock solution.  Animals were injected intravenously 
with either SB290157 (5 mg/kg) or 10% ethanol/saline vehicle daily from day 14 through 
day 18 and were randomly assigned to one of the following treatment groups: 1) rats that 
underwent the RUPP surgery receiving 5 mg/kg SB290157 (RUPP SB), n=9; 2) rats that 
underwent the RUPP surgery receiving 10% EtOH/Saline vehicle (RUPP Veh), n=7; 3) 
rats that underwent a sham surgery receiving 10% EtOH/Saline vehicle (Sham Veh), n=7; 
4) rats that underwent a sham surgery receiving 5 mg/kg SB290157 (Sham SB), n=6. 
Mean arterial pressure measurements and tissue collection 
 Mean arterial pressure (MAP) was measured as detailed in Chapter 1 via intra-
arterial catheter in unanesthetized restrained animals on day 19 of gestation and serum 
and plasma were harvested as described previously (Gilbert et al., 2010; Gilbert et al., 
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2007; Alexander et al., 2001).  Fetal and placental weights were collected from non-
resorbed pups.  Utero-placental units were selected from the ovarian, middle, and cervical 
uterine regions on the left horn and were fixed in 10% neutral buffered formalin for 
histological analysis. 
VEGF plasma assays 
Circulating free VEGF concentrations in EDTA plasma collected on day 19 of 
gestation were measured using commercially available kits for Mouse VEGF from R&D 
Systems (Quantikine, Minneapolis, MN) according to manufacturer’s directions and as 
described previously.  
C3a pressor response in nonpregnant and pregnant rats 
 To verify that C3a produces a transient increase in blood pressure (pressor 
response) in anesthetized, unrestrained nonpregnant rats as previously reported, we used 
the potent C3a analog peptide described by Ember et al (1991) 
(WWGKKYRASKLGLAR, AnaSpec, Fremont, CA) to induce a transient hypertension.  
C3a peptide was dissolved in 0.9% sterile saline (Baxter, Deerfield, IL) to make a 0.25 
mg/ml stock solution.   
Nonpregnant rats were injected with 3 mg ketamine (Phoenix, St. Joseph, MO) 
and 0.6 mg xylazine (AnaSed, Shenandoah, IA) and received a jugular catheter for 
peptide administration and a carotid catheter for blood pressure measurements as 
described above.  After the resting blood pressure stabilized for approximately 15 
minutes, C3a peptide (30 ug/kg) was given and blood pressures were again allowed to 
stabilize.  Once blood pressures returned to resting values, norepinephrine (Sigma-
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Aldrich, St. Louis, MO) was given (80 µg/kg) to serve as a positive control and verify the 
rat vasculature was responsive. 
Complement measurements 
C3a Serum concentrations were measured by Western immunoblot as previously 
described for guinea pig C3a (Regal et al., 2000) and as outlined in Chapter 1. Images 
were acquired using incubation with SuperSignal West Pico Maximum Sensitivity 
Substrate (Thermo Fisher Scientific, Rockford, IL) for 5 minutes, image capture with 
FluoroChem camera (AlphaInnotech, San Leadro, CA), and pixel density quantification 
with Image J (National Institutes of Health, Bethesda, MD). Dilutions of a standard pool 
of rat serum activated by yeast were used to construct a standard curve on each gel and a 
regression equation was used to calculate the relative amount of C3a in the unknown 
samples.  Relative amounts of C3a in each sample were expressed as C3a units/µl based 
on signal intensity of 1 µl of standard pool of rat serum activated by yeast. 
Total complement hemolytic activity.  The inverse dilution of serum that causes 50% 
hemolysis of sensitized sheep erythrocytes (CH50) was determined as an indicator of total 
complement pathway function as previously described in Chapter 1.  The ability of 
SB290157 to inhibit complement activation in vitro was also assessed by incubating 
SB290157 or 10% EtOH/saline vehicle with a pool of non-pregnant rat serum and 
determining whether the CH50 was affected.   
Statistical analyses 
 Data were analyzed using two-way ANOVA and are presented as mean ± SE. 
Differences were considered significant when p<0.05.  Three individual contrasts were 
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considered most relevant for comparison of means:  Sham Veh vs RUPP Veh, RUPP Veh 
vs RUPP SB, and Sham Veh vs Sham SB. In the acute study, relevant contrasts were 
pregnant vs nonpregnant and C3a vs SB + C3a. 
 
Results 
C3aR antagonism by SB290157 attenuates placental ischemia-induced hypertension 
 On gestational day 19, rats that underwent the RUPP procedure (n=7) had an 
increase in mean arterial pressure (MAP) when compared to those that received a sham 
surgery (n=7) (109±2 vs 94±2 mmHg, respectively) as measured by arterial catheter 
(Figure 13).  Antagonism of the C3aR with SB290157 significantly attenuated the 
hypertension in the RUPP animals (101±2 mmHg, n=9) with no effect on the Sham 
animals (95±2 mmHg, n=6) *p<0.05 for indicated comparisons. 
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Figure 13. Mean arterial pressure was increased in the RUPP Veh group (109±2 mmHg, 
n=7) compared to Sham Veh (94±2 mmHg, n=7).  SB290157 attenuated RUPP-induced 
hypertension (RUPP SB 101±2 mmHg, n=9) with no effect on the Sham group (Sham SB 
95±2 mmHg, n=6). Data is presented as mean ± SE, *p<0.05 for indicated comparisons.  
 
SB290157 does not alter VEGF in placental ischemia 
 Free plasma VEGF concentrations decreased slightly in vehicle-treated RUPP rats 
when compared to vehicle-treated Sham rats (RUPP Veh 1152.3±149.7 pg/ml, n=5, vs 
1424.14±138.6 pg/ml, n=7), but the difference did not reach statistical significance 
(Figure 14).  SB290157 did not have any effect on VEGF in RUPP or Sham rats (RUPP 
SB 1141±122.2 pg/ml, n=9, vs Sham SB 1430±149.7 pg/ml, n=6). 
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Figure 14. VEGF decreased slightly but not significantly in RUPP Veh rats 
(1152.3±149.7 pg/ml, n=5) as compared to Sham Veh (1424.1±138.6 pg/ml, n=7).  No 
changes occurred with administration of SB290157 in either the RUPP (RUPP SB 
1141±122.2 pg/ml, n=9) or Sham groups (Sham SB 1430±149.7 pg/ml, n=6). Data is 
presented as mean ± SE. 
 
SB290157 does not affect decreased fetal weights caused by placental ischemia but 
improves placental efficiency in RUPP dams 
 The RUPP procedure predictably resulted in fetal growth restriction (Figure 15) 
when compared to Sham (RUPP Veh 2.24±0.07 g, n=7 vs Sham Veh 2.52±0.07 g, n=7) 
(*p<0.05).  SB290157 did not improve fetal weights in the RUPP group and did not 
affect the Sham group (RUPP SB 2.20±0.07 g, n=8; Sham SB 2.51±0.07 g, n=6).  Fetal 
resorptions were not changed by SB290157 (data not shown). 
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 Placental weights were not different between RUPP Veh, Sham Veh, and Sham 
SB (0.45±0.02 g, n=7; 0.46±0.01 g, n=7; 0.45±0.01 g, n=6, respectively), but average 
total placental weight was decreased in the RUPP SB group (0.38±0.01 g, n=8) (Figure 
16).  Thus, placental efficiency (or mean pup weight per mean placental weight) in the 
RUPP SB group was significantly higher (5.77±0.13, n=8) than RUPP Veh (5.01±0.20, 
n=7) (*p<0.05) but was not different from Sham Veh (5.46±0.16, n=7) or Sham SB 
(5.57±0.20, n=6) (Figure 17). 
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Figure 15. As expected, the average fetal weight decreased in dams that underwent the 
RUPP surgery (RUPP Veh 2.24±0.07 g, n=7 vs Sham Veh 2.52±0.07 g, n=7).  SB290157 
did not restore fetal weights in the RUPP animals (RUPP SB 2.20±0.07 g, n=8) and had 
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no effect on the Sham group (Sham SB 2.51±0.07 g, n=6).  Data is presented as mean ± 
SE, *p<0.05 for indicated comparisons. 
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Figure 16. Average placental weight decreased in the RUPP SB group (0.38±0.01 g, 
n=8) vs the other three groups (Sham Veh 0.46±0.01 g, n=7; RUPP Veh 0.45±0.02 g, 
n=7; Sham SB 0.45±0.01 g, n=6). Data is presented as mean ± SE, *p<0.05 for indicated 
comparisons. 
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Figure 17.  Placental efficiency (total mean fetal weight:total mean placental weight) 
trended toward a decrease in the RUPP Veh as compared to Sham Veh, though the 
difference was not significant (RUPP Veh 5.01±0.20, n=7 vs Sham Veh 5.46±0.16, n=7).  
However, RUPP SB dams exhibited a significantly greater placental efficiency compared 
to RUPP Veh (RUPP SB 5.77±0.13, n=8) (*p<0.05).  No change occurred in the Sham 
dams with SB (Sham SB 5.57±0.20, n=6). Data is presented as mean ± SE. 
 
SB290157 decreases circulating C3a in RUPP dams but not Sham dams 
 As seen in Figure 18, RUPP Veh dams had increased circulating serum C3a as 
compared to Sham Veh (RUPP Veh 0.39±0.07 units C3a/µL, n=7 vs Sham Veh 
0.21±0.03, n=6) (*p<0.05).  RUPP animals receiving SB290157 had decreased C3a 
  72 
compared to RUPP Veh (RUPP SB 0.22±0.03, n=9) (*p<0.05), but C3a in Sham animals 
receiving SB290157 was not different (Sham SB 0.10±0.05, n=6). 
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Figure 18. The complement activation product C3a increased in serum in response to the 
RUPP procedure (RUPP Veh 0.39±0.07 units C3a/µL, n=7 vs Sham Veh 0.21±0.03, 
n=6), consistent with our previous findings that RUPP increases complement activation.  
C3a concentrations were decreased with SB290157 in the RUPP group (RUPP SB 
0.22±0.03, n=9) but not in the Sham rats (Sham SB 0.10±0.05, n=6).  Data is presented as 
mean ± SE, *p<0.05 for indicated comparisons. 
 
SB290157 inhibits the C3a-induced pressor response 
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 An intravenous bolus injection of 30 µg/kg C3a peptide in anesthetized, 
unrestrained pregnant dams on gestational day 19 resulted in a rapid and transient pressor 
response (36.9±5.7% increase from resting MAP, n=6) as measured by arterial catheter 
(Figure 19).  Resting blood pressure in pregnant anesthetized rats was 77.8±3.1 mmHg 
(data not shown).  The same dose of the peptide yielded a 35.8±6.8% increase from 
resting MAP in non-pregnant rats of a comparable age and size (n=8).  Resting blood 
pressure in non-pregnant anesthetized rats was 83.6±5.4 mmHg (data not shown). 
Contrary to reports by Proctor et al (2004), MAP was not affected by the 
SB290157 (100 µg/kg) bolus injection itself in non-pregnant rats (9.1±7.0% change from 
resting, n=5).  MAP was similarly unaffected in pregnant rats (2.3±2.5% change from 
resting, n=4). 
15 minutes following SB290157 administration, 30 µg/kg C3a peptide was given.  
SB290157 attenuated the C3a-induced pressor response (0.74±5.4% change from resting 
MAP in non-pregnant rats, n=5; 0.07±1.7% change from resting MAP in pregnant rats, 
n=4). 
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Figure 19. Unrestrained anesthetized rats given 30 ug/kg C3a peptide exhibited an 
increase in mean arterial pressure (MAP) from resting (non-pregnant 37.67±6.8% 
increase in MAP, n=7; pregnant 36.87±5.7% increase in MAP, n=6).  SB290157 (100 
ug/kg) itself did not have an effect on MAP (9.09±7.0% increase from resting in non-
pregnant, n=5; 2.25±2.51% increase from resting in pregnant, n=4) and completely 
abrogated the 30 ug/kg C3a analog-induced pressor response (0.74±5.4% change from 
resting in non-pregnant, n=5; 0.07±1.69% change from resting in pregnant, n=4). Data is 
presented as mean ± SE, *p<0.05 for indicated comparisons. 
 
SB290157 has no effect on CH50 in vivo or complement activation in vitro 
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To determine if SB290157 altered complement levels in vivo, we measured total 
hemolytic complement activity in plasma that uses antibody as an initiating event (Figure 
20).  There was no difference among any of the treatment groups (Sham Veh 2.40±0.23, 
n=6; RUPP Veh 2.59±0.67, n=7; RUPP SB 2.49±0.18, n=9; Sham SB 2.16±0.18, n=6).  
In vitro, we added SB290157 or 10% EtOH/saline vehicle (volume equivalent to 5 mg/kg 
based on total blood volume of a 300 g rat) to a standard rat serum pool.  Neither the 
presence of SB290157 nor vehicle had any impact on classical pathway activation in 
vitro in the CH50 assay (data not shown). 
 We exposed the same volume of SB290157 or 10% EtOH/saline to the same rat 
serum pool, this time in the presence of yeast to test alternative pathway complement 
activation measured by Western immunoblot.  Serum samples were taken at multiple 
timepoints to monitor the rate and extent of complement activation as it occurred. There 
was no difference in complement activation in the presence of SB290157 or the vehicle 
in this assay (data not shown). 
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Figure 20.  The complement activity of serum was assessed by the ability of the plasma 
to lyse antibody-sensitized sheep erythrocytes.  No differences were observed between 
any of the treatment groups (Sham Veh 2.40±0.23, n=6; RUPP Veh 2.59±0.67, n=7; 
RUPP SB 2.49±0.18, n=9; Sham SB 2.16±0.18, n=6). Data is presented as mean ± SE. 
 
SB290157 had no effect on circulating neutrophil concentrations in plasma 
Some studies have shown partial complement agonist activity in that acute 
administration of SB290157 caused a transient increase in blood pressure and 
neutropenia.  Therefore, circulating neutrophils (PMN) in the plasma from gestational 
day 19 were measured (Figure 21).  Though RUPP Veh tended to be decreased compared 
to Sham Veh, the difference did not reach statistical significance (0.21±0.08 x 107 
PMN/ml, n=6 vs 0.41±0.07 x 107 PMN/ml, n=7; p=0.06).  No difference in circulating 
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neutrophils was evident with SB290157 in either the RUPP or Sham group (0.34±0.08 x 
107 PMN/ml, n=9, 0.40±0.08 x 107 PMN/ml, n=6, respectively). 
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Figure 21.  Neutrophil concentrations did not change significantly between any of the 
treatment groups (Sham Veh 0.41±0.07 x 107 PMN/ml, n=7; RUPP Veh 0.21±0.08 x 107 
PMN/ml, n=6; RUPP SB 0.34±0.08 x 107 PMN/ml, n=9; Sham SB 0.40±0.08 x 107 
PMN/ml). Data is presented as mean ± SE. 
 
Discussion 
Complement activation is heightened in preeclampsia (Denny, 2012). The 
complement activation product C3a is anaphylatoxic (along with C4a and C5a) and plays 
numerous roles in cellular activation of certain leukocytes.  C3a is known to have direct 
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microvascular effects and modulate inflammatory factors, and C3a is increased in 
preeclamptic patients (Lynch et al., 2011).  Though C5a is a more potent chemoattractant, 
C3a and its precursor C3 are approximately 15 times more concentrated in the plasma as 
compared to C5a if complement is activated (Feinberg, 2006), making C3a-mediated 
activity a likely contributor to the development of hypertension. We therefore 
hypothesized that C3a is the critical complement activation product involved in placental 
ischemia-induced hypertension.  To this end, we examined both acute and chronic in vivo 
responses to a competitive nonpeptide antagonist to the C3a receptor. We hypothesized 
that this antagonist, SB290157, would reduce C3a-mediated cellular responses that may 
be important in hypertension and other damage associated with placental ischemia. 
Our data demonstrate that the C3aR antagonist SB290157 is an effective agent to 
ameliorate both chronic placental ischemia-induced hypertension and acute C3a-mediated 
pressor responses.  SB290157 has a demonstrated high efficacy and specificity for the 
C3a receptor in rat cells and does not disrupt C5a-mediated cellular responses in vitro 
(Ames et al., 2001).  However, Mathieu et al (2005) described some agonist activity of 
SB290157 in systems with high C3aR density, and others observed similar agonist 
properties in Chinese hamster ovary cells and human U937 cells (Scully et al., 2010). 
In our studies, mean arterial pressure (MAP) significantly increased in vehicle-
treated animals following the RUPP procedure, and this hypertension decreased in RUPP 
rats treated with SB290157 with no effect on the Sham animals.  No change occurred in 
plasma sFlt-1 concentrations with the RUPP procedure (data not shown) and free plasma 
VEGF tended to be decreased with the RUPP procedure in these experiments, but the 
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difference was not significant. Antagonism of the C3a receptor did not affect 
concentrations of plasma sFlt-1 (data not shown) or free plasma VEGF. Therefore, these 
data indicate that the decrease in free VEGF may not be due to increased plasma sFlt-1 
and alterations in free VEGF may occur prior to complement activation or acts as a 
parallel mechanism to contribute to hypertension.  
Though both fetal and placental weights were lowered in the RUPP SB group, the 
interaction of placental ischemia and C3aR antagonism may be involved in improving 
placental efficiency. Lim & Lappas (2012) provided immunohistochemical evidence that 
C3aR expression was decreased in the placentae of women with preeclampsia as 
compared to healthy pregnancies.  As Mathieu et al (2005) indicated, tissues with low 
C3aR expression do not experience the agonistic effects of SB290157.  Perhaps the 
beneficial effects of SB290157 in the RUPP model are due to a decrease in receptor 
expression or increase in receptor degradation in the placentae following placental 
ischemia. Immunohistochemical assessment of receptor density in the placenta following 
the RUPP procedure may shed some light on the validity of this process. 
Unexpectedly, circulating serum C3a levels decreased in the RUPP SB treatment 
group.  A true antagonist to the C3aR should not have any impact on complement 
activation, but should only inhibit cellular responses that result from C3a binding to its 
receptor.  Therefore, we speculate that SB290157 may be responsible for some additional 
activity in vivo due to its L-arginine moiety.  Qu et al (2009) noted that the L-arginine in 
SB290157 was essential for binding strength, but it also caused a shortened half-life and 
decreased bioavailability of whole-molecule SB290157.  If unbound SB290157 is 
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metabolized and the L-arginine group is freed, it is possible that nitric oxide (NO) 
synthesis is potentiated and hypertension is attenuated.  Thus, NO should be measured in 
future experiments using this compound. 
The possibility for degradation of SB290157 resulting in free L-arginine yields 
some potentially intriguing insights to understanding its pathway of action in vivo, 
especially during pregnancy.  Nitric oxide synthase (NOS) can be produced and 
expressed in the syncitiotrophoblast and catalyzes the reaction of L-arginine and NADPH 
to produce NO, a contributor to uterine vasodilation.  The NOS pathway has been 
inhibited by acutely administered L-arginine analogs to result in a substantial decrease in 
glomerular filtration rate and renal plasma flow and increase in renal vascular resistance 
in the pregnant rat (Molnar & Hertelendy, 1992).  The state of pregnancy enhances the 
response to L-arginine-induced changes in renal hemodynamics; changes in GFR, RPF, 
and vascular resistance are more robust in pregnant rats as compared to non-pregnant 
(Conrad et al., 2009).  L-arginine analogs (i.e. L-NG-nitroarginine methyl ester (L-
NAME)) hinder NO production by inhibiting NOS, resulting in hypertension in animal 
models (Molnar & Hertelendy, 1992). L-arginine, a necessary component for NO 
synthesis, has been shown to attenuate hypertension in sFlt-1-infused Harlan Sprague 
Dawley rats (Murphy et al., 2011) and in RUPP rats (Alexander et al., 2004).  It is 
possible, then, that the attenuation of RUPP-induced hypertension by SB290157 is partly 
due to the presence of free L-arginine.   
Future studies should assess whether complement is activated to result in an 
increase in C3a that is depleted by SB290157, or if complement activation is inhibited by 
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SB290157 itself in vivo.  SB290157 did not have inhibitory effects on alternative 
complement activation when exposed to yeast in a standard pool of rat serum, nor did it 
affect classical pathway activation when incubated with antibody-sensitized sheep 
erythrocytes (data not shown).  Thus, serum samples for C3a quantification should be 
collected to follow the time course of chronic administration. 
Our acute pressor response experiments support the observation of Proctor et al. 
(2006) that SB290157 blocked the increase in blood pressure following complement 
activation.  However, in contrast, our studies presented no evidence for neutropenia in the 
presence of SB290157.  SB290157 has been shown to block C3aR internalization in 
human neutrophils (PMN) (Ames et al., 2001), and PMN have been implicated as 
important in generating reactive oxygen species that contribute to oxidative stress, 
endothelial damage, and inflammation (Ishihara et al., 2004).  Additionally, PMN 
infiltration to ischemic tissues has been shown to lead to reactive oxygen species 
activation of the RhoA kinase pathway, which ultimately causes enhanced vascular 
reactivity (Mishra et al., 2011).  Activated monocytes and PMN are known to be present 
in preeclampsia (Powers et al., 2001; Vinatier et al., 1995; Haeger et al., 1992), and 
activation may occur via oxidative stress (Roberts et al., 2001).  Activation of PMN 
results in degranulation of the cell and release of various substances that act on the 
vasculature, such as elastase, which damages endothelial cell integrity, and toxic 
substances that also damage the endothelium and potentiate the inflammatory response 
(Greer et al., 1991). PMN are known to infiltrate ischemic tissue and antibodies to C5 
reduce tissue damage due to decreased PMN infiltration and activation in 
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ischemia/reperfusion injury (Vakeva et al., 1998).  Since our RUPP Veh dams had 
neutrophil counts trending downward, we suspect neutrophils may be sequestered in the 
placental tissue.  SB treatment in the RUPP group seemed to trend toward partial 
restoration of absolute circulating neutrophil count, so perhaps SB290157 is able to 
displace sequestered neutrophils.  A reasonable next step would be to check for 
neutrophil activation and/or sequestration in the placenta.   
Our studies are the first to examine the effects of the C3a receptor antagonist 
SB290157 in the context of placental ischemia.  SB290157 effectively attenuated 
hypertension in the RUPP model of placental ischemia-induced hypertension and did not 
alter free plasma VEGF concentrations, indicating an important role for C3a and/or its 
receptor in hypertension in a pathway distinct from VEGF. These data may be useful in 
developing specific and clinically feasible management strategies for gestational 
hypertension, and they also suggest further investigation of other complement activation 
products (i.e., C5a, C5b-9) and their possible role(s) in placental ischemia-induced 
hypertension. 
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Chapter 4 
Discussion 
Recently, we demonstrated that complement activation is important for placental 
ischemia-induced hypertension (Lillegard et al., 2013).  We used a complement 
activation inhibitor (sCR1) to interrupt the complement cascade in a rat model of 
preeclampsia known as the reduced utero-placental perfusion pressure (RUPP) model, 
which is well known to increase blood pressure in a pregnant rat on day 19 of gestation 
(Vest et al., 2012).  We found that RUPP rats that were given a saline vehicle had 
increased mean arterial pressure, increased serum concentrations of the complement 
activation product C3a, and reduced vascular endothelial growth factor (VEGF) on 
gestational day 19 when compared to their Sham counterparts.  sCR1 successfully 
reduced complement activation, evidenced by a marked decrease in circulating serum 
C3a levels.  Moreover, sCR1 attenuated the elevated mean arterial pressure in the RUPP 
animals with no effect on the Sham group.  These data indicate that complement 
inhibition is important in placental ischemia-induced hypertension, and that 
pharmacological manipulation of the complement system may be a new strategy for 
treatment of pregnancy-induced hypertension.  It is important to note that general 
complement inhibition is not a viable treatment route for preeclampsia because it 
potentiates maternal and fetal risk of infection, so it is necessary to explore which 
particular components of complement activation are associated with pregnancy-induced 
hypertension.   
  84 
Because the complement activation product C3a is vasoactive and highly 
concentrated in plasma following complement activation, we chose to target the C3a 
receptor to inhibit C3a-mediated cellular responses that may be key to placental 
ischemia-induced hypertension.  We induced placental ischemia-induced hypertension 
with the RUPP procedure in the rat on day 14 of a 21-day gestation.  RUPP dams had 
increased blood pressure and decreased pup weights on gestational day 19 when 
compared to Sham dams.  Antagonism of the C3a receptor with the competitive non-
peptide SB290157 ameliorated the increased blood pressure and did not restore VEGF, 
but it did improve placental efficiency in the RUPP dams.  These data indicate that 
actions involving the C3a receptor contribute to placental ischemia-induced hypertension, 
and antagonism at this receptor suggests a potentially viable method to attenuate 
hypertension and thus prolong gestation. 
Between these experiments, we observed a few variances in the cohorts that may 
warrant further consideration.  In the sCR1 study, intrauterine growth restriction with the 
RUPP procedure was not significant, perhaps due to an unusually small Sham cohort.  
We did see a significant decrease in concentrations of free plasma VEGF but no increase 
in circulating sFlt-1, presumably due to the absence of heparin in these animals.  In the 
SB290157 study, we had a reduction in average fetal weight in RUPP dams and no 
significant decrease in free plasma VEGF concentrations.  These inconsistencies 
complicate translation of our data across studies.  Further, evidence exists for several key 
differences between distributors of Sprague Dawley rats (i.e. Harlan vs Charles River) in 
the severity of endothelial-dependent artery relaxation after RUPP surgery (Crews et al., 
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2000; Gilbert et al., 2010) and hypertensive response to NO inhibition (Buhimschi et al., 
2001; Pollock & Rekito, 1998).  Studies using NO inhibition have recently elucidated 
differences between distributors in nephropathy susceptibility and systemic and renal 
hemodynamic responses (Griffin et al., 2012).  
Figure 22 outlines the current working model of preeclampsia with placental 
ischemia as the initiating event that incorporates the data from these studies.  Based on 
our findings, we hypothesize that placental ischemia causes increased complement 
activation and decreased free VEGF to result in hypertension.  Antagonism of the C3aR 
attenuated the hypertension and had no effect on free VEGF concentrations, indicating 
that the cellular actions mediated by the interaction of C3a and C3aR are important in 
placental ischemia-induced hypertension.  Because C5a stimulates similar cellular actions 
at its receptor, we include the possibility that C5a may also impact blood pressure.  The 
mechanism by which free VEGF decreases remains unclear, but we hypothesize that this 
change may occur prior to complement activation, indicated by the dashed arrow.  As 
these variables are tested, we may expand the scope of this hypothesis to examine effects 
on fetal health, how sFlt-1 is involved, or other possible mediators or mechanisms related 
to complement system activation that may lead to hypertension. 
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Figure 22. Working hypothesis. Our working hypothesis states that placental ischemia 
causes increased complement activation and decreased free VEGF to result in 
hypertension.  Cellular actions mediated by C3a at the C3aR contribute to hypertension. 
 
Several experiments are necessary given the current working hypothesis.  First, it 
is important to examine the relationship between VEGF and complement.  We have 
shown that the RUPP procedure results in hypertension and increased complement 
activation and previously, VEGF infusion has been shown to attenuate RUPP-induced 
hypertension (Gilbert et al., 2010). However, it is not known if VEGF infusion affects 
complement activation, and we did not observe any change in free plasma VEGF 
following complement inhibition. Therefore, we can infuse VEGF into rats receiving the 
RUPP surgery and take serum to measure complement activation (i.e., serum C3a) over 
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the course of the infusion.  If VEGF infusion prevents excessive complement activation, 
this data would suggest the RUPP-induced decrease in free VEGF leads to activation of  
the complement cascade to contribute to hypertension.  Because we observed a decrease 
in serum C3a in the RUPP rats with SB290157 treatment, future experiments should 
include taking serum samples every 24 hours over the course of the experiment.  It is 
important to identify if SB290157 is somehow inhibiting complement activation 
immediately following the RUPP procedure or if complement activation occurs and then 
is blocked. The mechanism by which SB290157 works in vivo must be more carefully 
examined if C3aR antagonism is to be pursued as a management strategy for maternal 
symptoms. 
The working hypothesis leads to some logical future directions. Effective 
management strategies for preeclampsia must consider both mother and fetus. C3aR 
antagonism decreased hypertension in the RUPP rats and increased placental efficiency, 
indicating the placenta was able to efficiently transfer resources to the fetus.  It would be 
interesting to examine changes in nutrient exchange with C3aR antagonism. Extensive 
long-term fetal studies must take place to identify any potential adverse developmental 
effects in these pups or in future generations. Also, because C3a and C5a act similarly, it 
is important to explore C5a and its interaction at its receptor.  Antagonism of the C5aR 
may attenuate placental ischemia-induced hypertension, and perhaps antagonism of both 
the C3aR and C5aR would attenuate the hypertension more than either receptor alone. 
Clinically, our data support the concept that the immune system plays a key role 
in placental ischemia-induced hypertension. Elevated concentrations of complement 
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activation products are associated with preeclampsia and are present before its onset.  
Therefore, carefully controlled manipulation of the complement system holds promise as 
a therapeutic strategy to manage the symptoms of preeclampsia.  A recent case study 
described the effect of the C5a receptor antagonist eculizumab in a woman with HELLP 
syndrome.  Antagonism of the receptor improved symptoms to lengthen gestation by a 
critical 17 days, allowing the fetus to mature and thus lessen neonatal health 
complications.  Certainly, our data add to the rationale to target complement activation 
products and/or receptors and offer compelling evidence to pursue these factors as a 
management strategy for preeclamptic patients. 
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